

Oxytocin Acts on Astrocytes in the Central Amygdala to Promote a Positive Emotional State

Jérôme Wahis^{1,†,§}, Damien Kerspern^{1,†}, Ferdinand Althammer^{2,†,§}, Angel Baudon^{1,†}, Stéphanie Goyon¹, Daisuke Hagiwara³, Arthur Lefèvre³, Benjamin Boury-Jamot⁴, Benjamin Bellanger¹, Marios Abatis⁴, Miriam Silva da Gouveia², Diego Benusiglio³, Marina Eliava³, Andrej Rozov⁵, Ivan Weinsanto¹, Hanna Sophie Knobloch-Bollmann⁶, Hong Wang⁷, Marie Pertin⁸, Perrine Inquimbert¹, Claudia Pitzer⁹, Jan Siemens⁷, Yannick Goumon¹, Benjamin Boutrel⁴, Pascal Darbon¹, Christophe Maurice Lamy¹⁰, Javier E. Stern¹¹, Isabelle Décosterd^{8,12}, Jean-Yves Chatton⁸, W. Scott Young¹³, Ron Stoop⁴, Pierrick Poisbeau¹, Valery Grinevich^{3,#}, Alexandre Charlet^{1,14,#,*}

¹ Centre National de la Recherche Scientifique and University of Strasbourg, UPR3212 Institute of Cellular and Integrative Neurosciences, Strasbourg, France. ² German Cancer Research Center (DKFZ), Heidelberg, Germany. ³ Department of Neuropeptide Research for Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany. ⁴ Center for Psychiatric Neurosciences, Hôpital de Cery, Lausanne University Hospital (CHUV), Lausanne, Switzerland. ⁵ OpenLab of Neurobiology, Kazan Federal University, Kazan, Russia and Department of Physiology and Pathophysiology, University of Heidelberg, Heidelberg, Germany. ⁶ Department of Molecular and Cellular Biology, Center for Brain Science, Harvard University, Cambridge, USA. ⁷ Department of Pharmacology, Heidelberg University, Heidelberg, Germany. ⁸ Pain center, Department of Anesthesiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland. ⁹ Interdisciplinary Neurobehavioral Core (INBC), Ruprecht-Karls-Universität, Heidelberg. ¹⁰ Division of Anatomy, Faculty of Medicine, University of Geneva, Geneva, Switzerland. ¹¹ Center for Neuroinflammation and Cardiometabolic Research, Georgia State University, Atlanta, USA. ¹² Department of Fundamental Neurosciences, Faculty of Biology and Medicine (FBM), University of Lausanne, Lausanne, Switzerland. ¹³ Section on Neural Gene Expression, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. ¹⁴ University of Strasbourg Institute for Advanced Study (USIAS), Strasbourg, France. [§] Present address: JW: Laboratory of Glia Biology, VIB-KU Leuven Center for Brain and Disease Research, KU Leuven Department of Neuroscience, Leuven, Belgium. FA:¹¹. [†] Equal first author. [#] senior author. ^{*} Corresponding author.

Corresponding Author

Dr. Alexandre Charlet, PhD

INCI, CNRS UPR3212

8, Allée du Général Rouvillois

67000 Strasbourg, France

Phone: (33) 6070 825 06

E-mail: acharlet@unistra.fr

SUMMARY

Oxytocin orchestrates social and emotional behaviors through modulation of neural circuits in brain structures such as the central amygdala (CeA). The long-standing dogma is that oxytocin signaling in the central nervous system occurs exclusively via direct actions on neurons. However, several findings over the last decades showed that astrocytes actively participate in the modulation of neuronal circuits. Here, we investigate the degree of astrocytes' involvement in oxytocin functions. Using astrocyte' specific gain and loss of function approaches, we demonstrate that CeA astrocytes not only directly respond to oxytocin, but are actually necessary for its effects on neuronal circuits and ultimately behavior. Our work identifies astrocytes as a crucial cellular substrate underlying the promotion of a positive emotional state by oxytocin. These results further corroborate that astrocytes are key regulators of neuronal circuits activity by responding to specific neuropeptidergic inputs, and opens up new perspectives to understand how neuromodulators gate brain functions.

INTRODUCTION

The neuropeptide oxytocin (OT) modulates key neurophysiological functions¹, including anxiety and pain, notably through its action on central amygdala (CeA) microcircuits^{2–5}. Oxytocin receptors (OTR) are expressed in the lateral and capsular part of the CeA (CeL)³. In this nucleus, OTR activation leads to increased firing of γ -aminobutyric acid (GABA) expressing interneurons. This directly inhibits projection neurons of the medial part of the CeA (CeM), the functional output of the CeA, thereby leading to clear behavioral outputs^{3,4,6}. Besides, the CeA is recognized as a major player in the pathophysiology of several neurological diseases, among which is neuropathic pain⁷, for which recent studies also suggest a critical involvement of astrocytes^{8–10} as well as the oxytocinergic system^{11,12}. However the possible involvement of astrocytes in the neuromodulatory effects of oxytocin has rarely been explored^{13–16}. That, despite the numerous findings of astrocytes active involvement in the regulation of neural circuits in a brain area specific manner^{17–20}, notably in the CeA²¹, with yet many controversies remaining about the mechanisms involved^{22,23}.

Herein, we employed patch-clamp techniques, calcium imaging, and behavioral assays to measure the consequences of *in vivo* and *ex vivo* direct manipulation of CeL astrocytes in both rats and mice. To this end, we used pharmacological approaches as well as genetic tools to ablate OTRs or expressed opsins specifically in CeL astrocytes. We demonstrate that astrocytes are a necessary component in the oxytocinergic modulation of CeA neuronal circuits and propose a mechanism by which astrocytes relay OT effects in the CeA by gating neuronal N-methyl-D-aspartate receptors (NMDAR) activation through release of the co-agonist D-serine. This ultimately leads to promotion

of the behavioral correlates of positive emotional states. With this study, we show for the first time that astrocyte-neuron communication is crucial for an efficient integration of positive emotions within the CeA, a structure involved in the processing of emotionally-relevant cues.

RESULTS

CeL Astrocytes Express Functional Oxytocin Receptors

To specifically investigate whether CeA astrocytes express OTRs, we performed fluorescence *in situ* hybridizations (FISH) on rat CeA sections and found overlap between OTR mRNA and an astrocyte marker, glutamine synthetase (Figure 1a-c). We quantified cells positive for both markers and found that a randomly (Figure S1a) distributed sub-population of about 13.6% of CeL astrocytes expresses the OTR mRNA (Figure 1c). We further corroborated this finding using the aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an astrocyte marker (Figure S1a), and confirmed it to be comparable in mice CeL astrocytes (Figures S1c-d; 2c).

To test whether endogenous activation of astrocytic OTR elicits physiological responses in CeL astrocytes, we performed calcium imaging in brain slices of rats using the calcium indicator Oregon Green® 488 BAPTA-1 (OGB1) and identified astrocytes through sulforhodamine 101 labelling (SR101) (Figure S2a). Indeed, measuring changes in intracellular calcium is the most commonly accepted readout of astrocytic activity²⁴. We first confirmed that SR101 positive cells of the CeL displayed typical electrophysiological properties of astrocytes (Figure S2b-c). We then expressed the opsin C1V1(t/t) under the oxytocin promoter through rAAVs (rAAV-OTp-C1V1(t/t)-mCherry) injected in the paraventricular, supraoptic, and accessory hypothalamic nuclei of rats, to enable light-evoked activation of oxytocin neurons and their distant axons localized within the CeL^{5,6} (Figure 1d-e, S1e). We found that light-driven activation of C1V1(t/t) expressing oxytocinergic axons rapidly evoked long-lasting and oscillating calcium transients in astrocytes (Figure 1f-h). These calcium transients persisted during bath application of

TTX, thereby excluding the possibility that they were evoked secondary to neuronal circuit activity.

OTR Activation Evokes Astrocytic Calcium Transients in CeL Astrocyte *Syncitium*

To confirm that the observed increase of intracellular calcium in CeL astrocytes is mediated by direct action on OTRs, we used the exogenous and OTR-selective agonist [Thr4Gly7]-oxytocin (TGOT). TGOT induced calcium transients in astrocytes, which were prevented by the incubation of the OTR antagonist [d(CH₂)⁵,Tyr(Me)²,Orn⁸]-vasotocin (dOVT) and remained unaffected by the presence of TTX (Figure 2a).

Next, we sought to reinforce the conclusions drawn from our pharmacological experiments by testing whether the OTRs expressed in CeL astrocytes are responsible for the TGOT-induced increase of calcium transients in these cells. To specifically ablate OTRs in CeL astrocytes, an rAAV vector allowing expression of Cre recombinase under the control of the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter (rAAV-GFAPp-GFP-IRES-Cre) was injected into the CeL of an OTR conditional knockout (OTR-cKO) mouse line in which *loxP* sites flank the OTR coding sequence²⁵ (Figure 2c). The injection of a control vector (rAAV-GFAPp-GFP) in OTR-cKO mice did not alter the OTR expression pattern, as 15.9% of astrocytes remained positive for OTR mRNA (Figure 2c), a proportion similar as what was found in rats CeL (Figure 1a-c). In comparison, CeL injection of the rAAV-GFAPp-IRES-Cre vector significantly reduced the number of OTR mRNA-expressing astrocytes to 1.2% (Figure 2c, S2e) but did not alter the OTR mRNA signals in neurons (Figure S2f), thus resulting in the CeL astrocyte-specific genetic

deletion of OTRs. We then performed calcium imaging in CeA slices of mice using the calcium indicator Rhod-2 and identified astrocytes through GFP fluorescence. In those animals, TGOT failed to evoke calcium transients in CeL astrocytes, which was in stark contrast to what we observed in control mice (Figure 2d).

Altogether, these findings suggest that OTR-expressing CeL astrocytes are fully equipped to respond in an autonomous fashion to the activity of oxytocinergic axonal projections arising from the hypothalamus in both rats and mice.

One interesting discrepancy is that up to 50% of CeL astrocytes responded to evoked release of OT or bath application of TGOT (Figure 1f-h, 2a) while OTR mRNA was detected in only 13 to 15% of CeL astrocytes (Figure 1a-c, S1a, 2a-c). Astrocyte calcium responses are known to spread through the astrocytes network via gap-junctions or paracrine communication through ATP release²⁰. We first applied purinergic antagonists, PPADS, Suramin, and A438079 but failed to reveal any changes in the proportion or magnitude of CeL astrocytes responses to TGOT (Figure 2b, S2d). This suggests that purinergic transmission is not involved in the sequential activation of the CeL astrocytes network after OTR activation. However, carbenexolone (CBX), a widely-used blocker of gap junctions, significantly decreased the proportion of CeL astrocytes responding to OTR activation (16.5%) without impairing the calcium response dynamics in the remaining responsive CeL astrocytes (Figure 2b).

These findings suggest that the initial OTR-induced activation of CeL astrocytes spreads across the CeL astrocytic network through gap junctions.

CeL Astrocytes are Sufficient to Recruit the CeL→CeM Neuronal Circuit.

To address the potential modulatory role of CeL astrocytes on the CeL→CeM neuronal circuit, we first asked whether CeL astrocyte activity was sufficient to solely modulate CeA neuronal circuits (Figure 3). Using rAAVs to express the light-gated opsin C1V1(t/t) under the control of the GFAP promoter (Figure 3a), we specifically targeted CeL astrocytes (Figure S3a) and tested the effect of light-evoked calcium transients elicited in CeL astrocytes on the CeL→CeM neuronal circuit (Figure 3b).

We hypothesized that a form of astrocytes-mediated neuromodulation could reveal itself through the presence of slow inward currents (SICs), a hallmark of neuronal NMDAR activation by astrocytes^{26,27}. SICs were indeed detected in CeL neurons (Figure 3c, S3b) and their frequency significantly increased after light-evoked calcium transients in CeL astrocytes (Figure 3c). To assess whether this increase in the SICs frequency is sufficient to increase excitability and ultimately firing in CeL neurons, we next performed *ex vivo* patch-clamp recordings of action potentials (APs) in CeL neurons upon CeL astrocytes stimulation (Figure 3b). We found that light-evoked calcium transients in CeL astrocytes led to an increase of APs frequencies in CeL neurons (Figure 3d). Crucially, this effect was prevented if we first loaded the Ca²⁺ chelator BAPTA into the CeL astrocytes syncytium²⁸ (Figure S3c).

Given that the CeM is the main output of the CeA, we then conducted *ex vivo* patch-clamp recordings of inhibitory post-synaptic currents (IPSCs) in CeM projection neurons (Figure 3b), whose frequency is known to increase after CeL interneurons firing³⁻⁵. Indeed, we found that light-evoked calcium transients in CeL astrocytes led to an increase of IPSCs frequencies in CeM neurons (Figure 3e) which was also prevented by BAPTA

infusion in the CeL astrocytes syncytium (Figure S3d). Altogether, these results indicate that CeL astrocytes activity is sufficient to modulate the CeL→CeM neuronal circuit.

CeL Astrocytes are Necessary for the CeL→CeM Neuronal Circuit Modulation by OTR Activation.

We then further examined whether CeL astrocytes are required to support the oxytocinergic modulation of the CeL→CeM neuronal circuit. We repeated the measurement of neuronal properties (Figure 3) and found that CeL neurons' SICs and APs frequencies, as well as CeM neurons' IPSCs frequency, were significantly increased after TGOT application in both rats and mice (Figure 4a1-a3, 4b1-b3; S4a).

Next, we loaded the Ca^{2+} chelator BAPTA into the rat CeL astrocytes syncytium (Figure 4a). BAPTA loading of CeL astrocytes significantly reduced the OTR-induced increase of SICs and APs frequencies in CeL neurons as well as the increase in IPSCs frequencies in CeM neurons (Figure 4a1-3). These results indicate the necessity of functional CeL astrocytes for the OTR-mediated recruitment of the CeL→CeM neuronal circuit.

To further verify that the OTR-induced modulation of the CeL→CeM neuronal circuit depends on OTRs present on CeL astrocytes, we specifically ablated OTRs in CeL astrocytes of OTR-cKO mice (Figure 2c, S2e-f, 4b). In accordance with our previous results using pharmacological inactivation of astrocytes in rats, the specific deletion of OTR in mice CeL astrocytes significantly decreased the TGOT-induced increase of both SICs and APs frequencies in CeL neurons, as well as in IPSCs frequency in CeM neurons

(Figure 4b1-3). These results highlight the necessity of OTR expression in CeL astrocytes for the OTR-mediated recruitment of the CeL→CeM neuronal circuit.

CeL Astrocytes Recruit the CeL→CeM Neuronal Circuit through NMDAR modulation

We then sought to confirm that the activation of neuronal NMDAR, which is underlying the presence of SICs^{26,27}, is indeed a key component of CeL astrocyte-to-CeL neuron communication (Figure 5a-b). While the blockade of NMDAR with (2R)-amino-5-phosphonopentanoate (AP5, glutamate site) did not alter CeL astrocytic responses to TGOT (Figure S5a), AP5 prevented TGOT-induced modulation of SICs and APs frequencies in CeL neurons (Figure 5c-d). Moreover, OTR-induced CeL astrocyte-mediated SICs were linked to the activation of NR2B containing NMDARs, since ifenprodil prevented only the TGOT-induced SICs frequency increase (Figure 5c). We next tested whether repeated TGOT applications consistently modulate the CeL→CeM neuronal circuit via OTR-specific activation to assess the role of the NMDAR pathway in TGOT responsive CeM neurons (Figure S5b). We found that both AP5 and 5,7-dichlorokynurenic acid (DCKA, a blocker of the NMDAR glycine co-agonist site) significantly reduced the TGOT-evoked increase of IPSCs frequencies in CeM neurons (Figure S5c). On the contrary, the blockade of the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) had only a limited effect (Figure S5d). These results indicate that the oxytocin signal is directly conveyed from CeL astrocytes to CeL neurons via neuronal NMDAR activation.

We next sought to identify the molecular agent released by CeL astrocytes that gates the increase in CeL neuronal NMDAR activation. We used D-amino-acid oxidase (DAAO) to selectively catabolize the NMDAR co-agonist D-serine, a major astrocytic gliotransmitter^{29–31}. TGOT had no effect after DAAO incubation, but subsequent incubation of the same cells in D-serine-containing ACSF partially restored the TGOT-mediated increased of IPSCs frequencies in CeM neurons (Figure 5e). Altogether, these data suggest that OTR-mediated activation of CeL astrocytes leads to the release of D-serine, allowing an increased activation of NMDAR in CeL GABAergic interneurons which, by increasing these neurons firing rate, leads in an increase of IPSCs frequencies downstream of the circuit, in CeM projection neurons.

CeL Astrocytes are Sufficient to Modulate CeA Behavioral Correlates of Positive Emotional State and are Necessary for their OTR-mediated Modulation

Finally, we aimed to determine whether the CeL astrocyte-mediated modulation of the CeL→CeM neuronal circuit by OTR activation contributes to known CeA behavioral correlates. Since the CeA is a key structure in the regulation of pain-associated disorders³² and assigns emotionality to salient external stimuli³³, we first tested the effect of TGOT on increased pain sensitivity and anxiety exhibited by neuropathic rats 4 weeks after a spared nerve injury surgery procedure^{34,35} (SNI; Figure 6a). As neuropathy may cause synaptic changes in the amygdala^{7,36}, we conducted *ex vivo* patch-clamp recordings of IPSCs in CeM projection neurons 4 weeks after SNI or sham surgery. The TGOT-induced increase of IPSCs frequency was strictly similar in both conditions (Figure S6a4), indicating that the OTR-induced modulation of the CeL→CeM neuronal circuit is

not altered after induction of SNI. Cannulae-guided micro-infusion of TGOT into the CeL slightly reduced mechanical hyperalgesia (Figure 6a1, S6a1) and clearly reduced anxiety levels in neuropathic animals (Figure 6a2, S6a2). We then performed similar experiments on SNI animals in which C1V1(t/t) was expressed under the control of a GFAP promoter in the CeL. Light-evoked stimulation of CeL astrocytes did not visibly affect mechanical pain thresholds of neuropathic animals, but was sufficient to reduce their anxiety (Figure 6a1-a2, S6a1-a2). Since the amygdala is critically involved in the regulation of emotions³⁷, we performed a conditioned place preference test (CPP) to assess if the OTR-induced modulation of the CeL→CeM pathway is linked to the emotional component of pain. Both cannulae-guided micro-infusion of TGOT in CeL and light-evoked activation of C1V1(t/t)-expressing CeL astrocytes induced a strong place preference in neuropathic and sham-operated rats (Figure 6a3, S6a3).

To confirm that the OTR-induced modulation of the observed behaviors strictly depends of OTR present on CeL astrocytes, we specifically ablated OTRs in mice CeL astrocytes (Figure 2c, S2e-f, 6b) and tested the effect of TGOT on increased pain sensitivity and anxiety exhibited by neuropathic mice 4 weeks after a spared nerve injury surgery procedure³⁸ (SNI; Figure 6b). Cannula-guided micro-infusion of TGOT in CeL did not change mechanical hyperalgesia (Figure 6b1, S6b1) but reduced anxiety levels in control neuropathic animals (Figure 6b2, S6b2), an effect that was prevented by the CeL astrocyte specific deletion of OTRs (Figure 6b2). As previously shown in rats (Figure 6a3), we tested mice for CPP and found a strong place preference effect of micro-infusion of TGOT in CeL in both neuropathic and sham-operated control mice, which was absent after deletion of OTR in CeL astrocytes (Figure 6b3, S6b3).

Altogether, these findings point towards the OTR-mediated signaling in CeL astrocytes as a counterbalancing mechanism supporting the positive emotional valence under both chronic pain and healthy states. It indicates that the OTR-astrocytes mediated modulation of the CeL→CeM neuronal circuit is not only involved in the regulation of hyperalgesia or anxiety but also represents a more general cellular substrate underlying the promotion of a positive emotional state (Figure 7).

DISCUSSION

In addition to their classical functions related to structural and metabolic support, modulation of synaptic transmission and transmitter uptake and release, astrocytes have emerged as key players in intricate and diverse glia-neuronal network interactions¹⁹. However, the functional relevance of astro-neuronal interactions in the modulation of complex social and emotional behaviors remains elusive. Following the initial experiments on OTRs in cultured astrocytes¹⁵, we sought to investigate the role of these cells in OTR signaling in the CeA, a structure critically involved in the processing of emotionally-relevant information. We showed that CeL astrocytes play a critical role in the oxytocin-induced modulation of the CeL→CeM neuronal circuit in two rodent species, rats and mice. Here we report that a subpopulation of CeL astrocytes express functional OTR and convey the oxytocin signal among other (OTR-negative) astrocytes of the CeL through gap junctional coupling. This recruitment of the CeL astrocytes syncytium leads to an NMDAR-mediated tuning of CeA neuronal circuits. At the behavioral level, this oxytocin-mediated modulation of the astro-neuronal network of the central amygdala might promote a positive emotional state.

The amygdala is a key region for emotional processing³⁷ with a clear involvement in pain regulation and particularly persistent pain, which impacts ~8% of the global population⁷. On the other hand, oxytocin is a neuropeptide well known to act on various behaviors throughout the cycle of life, with major involvement in a broad variety of physiological functions, all directed toward well-being, emotional balance and ultimately species survival^{1,39}. In this regard, it is interesting to observe that our results suggest that the oxytocin-induced modulation of CeA networks not only attenuates hypersensitivity

symptoms related to nociception in itself, but more generally improves the positive emotional valence of the animals even under pain-free conditions. Pain management is a clinically difficult topic, and most of the newly developed analgesic drugs have failed or not met expectations and patients' needs. Therefore, it might be particularly relevant to consider new therapeutic strategies aiming at alleviating the pain spectrum globally, for example by targeting the oxytocin system, to improve the overall patient well-being.

The oxytocinergic regulation of neural circuits and oxytocin's physiological functions is presently under intense scrutiny^{6,40–46}. Yet, to the best of our knowledge, these studies were solely based on the hypothesis that oxytocin signaling occurs predominantly in neurons, despite a sparse number of independent studies demonstrating expression of OTR in glia, notably astrocytes^{13,15,16,47,48}. Here, we propose a novel mechanism implicating astrocytes as key contributors of oxytocin action. The induction of long-lasting calcium oscillations in astrocytes following OTR activation leads to a sustained modulation of the CeL→CeM neuronal circuit, affecting known CeA functions such as emotional valence regulation. It may seem counter-intuitive that without a pristine astroglial function, CeA neurons appear unaffected by OTR activation, despite their clear transcription of OTR mRNA. We hypothesize that OTR-induced activation of CeL astrocytes gates CeL neurons responses to oxytocin, and probably other synaptic inputs, through sustained (co-) activation of NMDARs. Such mechanism of astrocytes to neuron communication through activation of extra-synaptic NMDARs has also been proposed by other studies to favor a synchronous increase in excitability across an ensemble of neurons^{49,50}. In particular, activation of G_q or G_{i/o} G-protein coupled receptors (GPCRs) specifically in astrocytes enhances neuronal excitability and ultimately firing⁵¹, a result which could parallel the

activation of the same signaling pathways here by specific OTR activation, and GPCRs are known to be coupled to either of G_q or $G_{i/o}$ proteins⁵². This proposed mechanism would allow for a synchronized and long-lasting switch in the gain of the CeA neuronal circuits, thereby amplifying the effect of oxytocin on CeA outputs in both the spatial and temporal domains. In light of the predominantly non-synaptic OT release from axons *en passant*, which could lead to CeL-restricted micro-volume transmission of the neuropeptide^{53,54}, it seems plausible that astrocytes relay and amplify oxytocin signaling to neurons. This would provide control over the oxytocin effect on neuronal circuits, as has already been proposed for other neuromodulators and neurotransmitters^{55,56}. The different dynamics and connectivity of astro-neuronal networks provide new insights in the regulation of brain functions and ultimately animal behavior⁵⁷, with a complexity yet to be unraveled^{20,22,58}. From a larger perspective, our results further confirm that astrocytes are functionally diverse and can regulate central nervous system functions in a network-specific manner^{19,59,60}. Therefore, the study of astrocyte-neuron interactions is essential for a better comprehension of both physiological and pathological mechanisms affecting brain function^{20,60,61}.

Given that oxytocin modulates emotions and behaviors through a variety of actions on the peripheral and central nervous system^{2,62–64}, our study adds a novel mechanism of oxytocin action: the modulation of astrocyte-neuron interactions. This mechanism underpins the oxytocinergic promotion of a positive emotional state, opening up new perspectives for studying the role of astroglial-neuronal networks in the modulation of emotional experiences^{57,65}, notably by neuropeptidergic systems⁶⁶. On a broader scope, our present results demonstrate that the astroglia-mediated effects of oxytocin provide a

new basis for the exploration of pathophysiologic mechanisms and enlighten a new vision of interplay between neuropeptides and glia that bears a general value for a better understanding of functional brain organization. This opens up new possibilities of research about the neuronal/glial substrates underlying positive emotional states, which is highlighted in our working model (Figure 7). The development of prospective treatments for somatic and mental diseases in humans may indeed be helped by targeting the oxytocin or other neuromodulators systems, and their joint action on multiple CNS cell types.

ACKNOWLEDGEMENTS

This work was supported by the IASP Early Career Research grant 2012, FP7 Career Integration grant 334455, Initiative of Excellence (IDEX) Attractiveness grant 2013, IDEX Interdisciplinary grant 2015, University of Strasbourg Institute for Advanced Study (USIAS) fellowship 2014-15, Foundation Fyssen research grant 2015, NARSAD Young Investigator Grant 24821, ANR JCJC grant (to AC); ANR-DFG grant GR 3619/701 (to AC and VG); the Schaller Research Foundation, DFG grant GR 3619/13-1, DFG within the Collaborative research Center SFB 1134, (to VG) and SFB 1158 (to CP and VG); SNSF-DFG grant GR 3619/8-1 (to RS and VG), Fritz Thyssen foundation (to VG); Alexander von Humboldt Foundation (to DH); Fyssen foundation and PROCOP grant and SFB1158 seed grant for young scientists (to AL); Research Foundation - Flanders, fellowship (12V7519N) (to JW); Russian science foundation RSF (17-75-10061) and the Program of Competitive Growth of Kazan University (to AR); the intramural research program of the NIMH (ZIAMH002498) (to WSY); National Institutes of Health grants R01NS094640 and R01HL090948 (to JES). The authors thank Vincent Lelièvre for *in situ* hybridization advices; Romain Goutagny for *in vivo* optogenetics assistance; Fulvio Magara for anxiety behavior advices; Barbara Kurpiers and the Interdisciplinary Neurobehavioral Core Facility of Heidelberg University for experiments performed there; Sophie Reibel, Dominique Ciocca and the Chronobiotron UMS 3415 for all animal care; Thomas Splettstoesser (www.scistyle.com) for its initial help with the preparation of figures.

AUTHOR CONTRIBUTIONS

Conceptualization, AC; Methodology, AC, BBo, CML, CP, DK, FA, ID, JW, JYC, PD, PP, RS, VG, WSY, YG; Analysis, AC, BBe, BBJ, CML, DK, FA, HSKB, JW, SG; *In situ* hybridization, DH, FA, HSKB, HW, JS, ME; Immunohistochemistry, AL, DH, FA, JW, ME, MdSG; *Ex vivo* patch-clamp electrophysiology, AB, AC, JW, SG, DK, IW, BBe, MA; *Ex vivo* calcium imaging, AB, CML, DK, JW; Astrocytes characterization, AR, DK, IW, ME, SG; Behavior, AC, BBJ, DK, JW; Mice line validation, WSY; Viral vectors validation, MdSG, ME, VG; Spared nerve injuries, PI, MP; Writing, AC, BBo, JES, JYC, JW, RS, VG; Funding acquisition AC, VG; Supervision, AC; Project administration, AC.

DECLARATION OF INTERESTS

The authors declare no competing interest

REFERENCES

1. Lee, H. J., Macbeth, A. H., Pagani, J. H. & Scott Young, W. Oxytocin: The great facilitator of life. *Prog. Neurobiol.* **88**, 127–151 (2009).
2. Eliava, M. *et al.* A New Population of Parvocellular Oxytocin Neurons Controlling Magnocellular Neuron Activity and Inflammatory Pain Processing. *Neuron* **89**, 1291–304 (2016).
3. Huber, D., Veinante, P. & Stoop, R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. *Science* **308**, 245–8 (2005).
4. Viviani, D. *et al.* Oxytocin selectively gates fear responses through distinct outputs from the central amygdala. *Science* **333**, 104–7 (2011).
5. Knobloch, H. S. *et al.* Evoked axonal oxytocin release in the central amygdala attenuates fear response. *Neuron* **73**, 553–66 (2012).
6. Hasan, M. T. *et al.* A Fear Memory Engram and Its Plasticity in the Hypothalamic Oxytocin System. *Neuron* **103**, 133-146.e8 (2019).
7. Neugebauer, V., Li, W., Bird, G. C. & Han, J. S. The amygdala and persistent pain. *Neuroscientist* **10**, 221–234 (2004).
8. Eto, K., Kim, S. K., Takeda, I. & Nabekura, J. The roles of cortical astrocytes in chronic pain and other brain pathologies. *Neurosci. Res.* **126**, 3–8 (2018).
9. Hansen, R. R. & Malcangio, M. Astrocytes - Multitaskers in chronic pain. *Eur. J. Pharmacol.* **716**, 120–128 (2013).
10. Ji, R.-R. R., Berta, T. & Nedergaard, M. Glia and pain: Is chronic pain a gliopathy? *Pain* **154**, S10–S28 (2013).
11. Poisbeau, P., Grinevich, V. & Charlet, A. Oxytocin Signaling in Pain: Cellular, Circuit, System, and Behavioral Levels. *Curr. Top. Behav. Neurosci.* (2017). doi:10.1007/7854_2017_14
12. Rash, J. a, Aguirre-Camacho, A. & Campbell, T. S. Oxytocin and pain: a systematic review and synthesis of findings. *Clin. J. Pain* **30**, 453–62 (2014).
13. Kuo, J., Hariri, O. R. & Micevych, P. An interaction of oxytocin receptors with metabotropic glutamate receptors in hypothalamic astrocytes. *J. Neuroendocrinol.* **21**,

- 1001–6 (2009).
14. Parent, A.-S. *et al.* Oxytocin Facilitates Female Sexual Maturation through a Glia-to-Neuron Signaling Pathway. *Endocrinology* **149**, 1358–1365 (2008).
15. Di Scala-Guenot, D., Mouginot, D. & Strosser, M.-T. Increase of intracellular calcium induced by oxytocin in hypothalamic cultures astrocytes. *Glia* **11**, 269–276 (1994).
16. Wang, P., Qin, D. & Wang, Y.-F. Oxytocin Rapidly Changes Astrocytic GFAP Plasticity by Differentially Modulating the Expressions of pERK 1/2 and Protein Kinase A. *Front. Mol. Neurosci.* **10**, 1–14 (2017).
17. Adamsky, A. *et al.* Astrocytic Activation Generates De Novo Neuronal Potentiation and Memory Enhancement. *Cell* 1–13 (2018). doi:10.1016/j.cell.2018.05.002
18. Allen, N. J. Astrocyte regulation of synaptic behavior. *Annu. Rev. Cell Dev. Biol.* **30**, 439–63 (2014).
19. Khakh, B. S. & Deneen, B. The Emerging Nature of Astrocyte Diversity. *Annu. Rev. Neurosci.* **42**, 187–207 (2019).
20. Verkhratsky, A. & Nedergaard, M. Physiology of Astroglia. *Physiol. Rev.* **98**, 239–389 (2018).
21. Martin-Fernandez, M. *et al.* Synapse-specific astrocyte gating of amygdala-related behavior. *Nat. Neurosci.* **20**, 1540–1548 (2017).
22. Bazargani, N. & Attwell, D. Astrocyte calcium signaling: the third wave. *Nat. Neurosci.* **19**, 182–189 (2016).
23. Savtchouk, I. & Volterra, A. Gliotransmission: Beyond Black-and-White. *J. Neurosci.* **38**, 14–25 (2018).
24. Shigetomi, E., Patel, S. & Khakh, B. S. Probing the Complexities of Astrocyte Calcium Signaling. *Trends Cell Biol.* **26**, 300–12 (2016).
25. Lee, H. J., Caldwell, H. K., Macbeth, A. H., Tolu, S. G. & Young, W. S. A conditional knockout mouse line of the oxytocin receptor. *Endocrinology* **149**, 3256–3263 (2008).
26. Perea, G. & Araque, A. Properties of synaptically evoked astrocyte calcium signal reveal synaptic information processing by astrocytes. *J. Neurosci.* **25**, 2192–203 (2005).

27. Shigetomi, E., Bowser, D. N., Sofroniew, M. V & Khakh, B. S. Two forms of astrocyte calcium excitability have distinct effects on NMDA receptor-mediated slow inward currents in pyramidal neurons. *J. Neurosci.* **28**, 6659–63 (2008).
28. Jourdain, P. *et al.* Glutamate exocytosis from astrocytes controls synaptic strength. *Nat. Neurosci.* **10**, 331–9 (2007).
29. Mothet, J.-P. *et al.* Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine. *Proc. Natl. Acad. Sci.* **102**, 5606–5611 (2005).
30. Oliet, S. H. R. & Mothet, J.-P. Regulation of N-methyl-D-aspartate receptors by astrocytic D-serine. *Neuroscience* **158**, 275–83 (2009).
31. Robin, L. M. *et al.* Astroglial CB1 Receptors Determine Synaptic D-Serine Availability to Enable Recognition Memory. *Neuron* **0**, 1–10 (2018).
32. Neugebauer, V., Galhardo, V., Maione, S. & Mackey, S. C. Forebrain pain mechanisms. *Brain Res. Rev.* **60**, 226–42 (2009).
33. Sah, P., Faber, E. S. L., Lopez De Armentia, M. & Power, J. The amygdaloid complex: anatomy and physiology. *Physiol. Rev.* **83**, 803–34 (2003).
34. Alba-Delgado, C., Cebada-Aleu, A., Mico, J. A. & Berrocoso, E. Comorbid anxiety-like behavior and locus coeruleus impairment in diabetic peripheral neuropathy: A comparative study with the chronic constriction injury model. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **71**, 45–56 (2016).
35. Yalcin, I. *et al.* The sciatic nerve cuffing model of neuropathic pain in mice. *J. Vis. Exp.* 1–7 (2014). doi:10.3791/51608
36. Han, J. S. & Neugebauer, V. *Synaptic plasticity in the amygdala in a visceral pain model in rats. Neuroscience Letters* **361**, (2004).
37. Phelps, E. A. & LeDoux, J. E. Contributions of the Amygdala to Emotion Processing: From Animal Models to Human Behavior. *Neuron* **48**, 175–187 (2005).
38. Yalcin, I. & Barrot, M. The anxiodepressive comorbidity in chronic pain. *Curr Opin Anaesthesiol* **27**, 520–527 (2014).
39. Grinevich, V. & Stoop, R. Interplay between Oxytocin and Sensory Systems in the

- Orchestration of Socio-Emotional Behaviors. *Neuron* **99**, 887–904 (2018).
40. Ferretti, V. *et al.* Oxytocin Signaling in the Central Amygdala Modulates Emotion Discrimination in Mice. *Curr. Biol.* **29**, 1938–1953.e6 (2019).
 41. Hung, L. W. *et al.* Gating of social reward by oxytocin in the ventral tegmental area. *Science* **357**, 1406–1411 (2017).
 42. Marlin, B. J., Mitre, M., D'amour, J. A., Chao, M. V. & Froemke, R. C. Oxytocin enables maternal behaviour by balancing cortical inhibition. *Nature* **520**, 499–504 (2015).
 43. Menon, R. *et al.* Oxytocin Signaling in the Lateral Septum Prevents Social Fear during Lactation. *Curr. Biol.* **28**, 1066–1078.e6 (2018).
 44. Nardou, R. *et al.* Oxytocin-dependent reopening of a social reward learning critical period with MDMA. *Nature* **569**, 116–120 (2019).
 45. Oettl, L. L. *et al.* Oxytocin Enhances Social Recognition by Modulating Cortical Control of Early Olfactory Processing. *Neuron* **90**, 609–621 (2016).
 46. Xiao, L., Priest, M. F., Nasenbeny, J., Lu, T. & Kozorovitskiy, Y. Biased Oxytocinergic Modulation of Midbrain Dopamine Systems. *Neuron* **95**, 368–384.e5 (2017).
 47. Mitre, M. *et al.* A Distributed Network for Social Cognition Enriched for Oxytocin Receptors. *J. Neurosci.* **36**, 2517–2535 (2016).
 48. Yoshida, M. *et al.* Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. *J. Neurosci.* **29**, 2259–71 (2009).
 49. Fellin, T. *et al.* Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. *Neuron* **43**, 729–43 (2004).
 50. Angulo, M. C., Kozlov, A. S., Charpak, S. & Audinat, E. Glutamate released from glial cells synchronizes neuronal activity in the hippocampus. *J. Neurosci.* **24**, 6920–6927 (2004).
 51. Durkee, C. A. *et al.* G i/o protein-coupled receptors inhibit neurons but activate astrocytes and stimulate gliotransmission. *Glia* **67**, 1076–1093 (2019).
 52. Busnelli, M. *et al.* Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. *J. Biol. Chem.* **287**, 3617–3629 (2012).

53. Chini, B., Verhage, M. & Grinevich, V. The Action Radius of Oxytocin Release in the Mammalian CNS: From Single Vesicles to Behavior. *Trends Pharmacol. Sci.* **38**, 982–991 (2017).
54. Grinevich, V., Knobloch-Bollmann, H. S., Eliava, M., Busnelli, M. & Chini, B. Assembling the Puzzle: Pathways of Oxytocin Signaling in the Brain. *Biol. Psychiatry* **79**, 155–164 (2016).
55. Hirase, H., Iwai, Y., Takata, N., Shinohara, Y. & Mishima, T. Volume transmission signalling via astrocytes. *Philos. Trans. R. Soc. B Biol. Sci.* **369**, 20130604–20130604 (2014).
56. Kastanenka, K. V. *et al.* A roadmap to integrate astrocytes into Systems Neuroscience. *GLIA* (2019). doi:10.1002/glia.23632
57. Oliveira, J. F., Sardinha, V. M., Guerra-Gomes, S., Araque, A. & Sousa, N. Do stars govern our actions? Astrocyte involvement in rodent behavior. *Trends Neurosci.* **38**, 535–549 (2015).
58. Volterra, A., Liaudet, N. & Savtchouk, I. Astrocyte Ca(2+) signalling: an unexpected complexity. *Nat. Rev. Neurosci.* **15**, 327–35 (2014).
59. Haim, L. Ben & Rowitch, D. Functional diversity of astrocytes in neural circuit regulation. *Nat. Rev. Neurosci.* **18**, 31–41 (2016).
60. Khakh, B. S. & Sofroniew, M. V. Diversity of astrocyte functions and phenotypes in neural circuits. *Nat. Neurosci.* **18**, 942–52 (2015).
61. Filous, A. R. & Silver, J. “Targeting astrocytes in CNS injury and disease: A translational research approach”. *Prog. Neurobiol.* **144**, 173–187 (2016).
62. Marlin, B. J. & Froemke, R. C. Oxytocin modulation of neural circuits for social behavior. *Dev. Neurobiol.* **77**, 169–189 (2017).
63. Morales-Soto, W. & Gulbransen, B. D. Enteric Glia: A New Player in Abdominal Pain. *Cell. Mol. Gastroenterol. Hepatol.* **7**, 433–445 (2019).
64. Poisbeau, P., Grinevich, V. & Charlet, A. Oxytocin Signaling in Pain: Cellular, Circuit, System, and Behavioral Levels. in *Current Topics in Behavioral Neurosciences* 289–320 (Springer, Berlin, Heidelberg, 2017). doi:10.1007/7854

65. Bender, C. L., Calfa, G. D. & Molina, V. A. Astrocyte plasticity induced by emotional stress: A new partner in psychiatric physiopathology? *Prog. Neuro-Psychopharmacology Biol. Psychiatry* **65**, 68–77 (2016).
66. Meyer-Lindenberg, A., Domes, G., Kirsch, P. & Heinrichs, M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. *Nat. Rev. Neurosci.* **12**, 524–38 (2011).
67. Shigetomi, E. *et al.* Imaging calcium microdomains within entire astrocyte territories and endfeet with GCaMPs expressed using adeno-associated viruses. *J. Gen. Physiol.* **141**, 633–647 (2013).
68. Decosterd, I. & Woolf, C. J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. *Pain* **87**, 149–158 (2000).
69. Ikegaya, Y., Le Bon-Jego, M. & Yuste, R. Large-scale imaging of cortical network activity with calcium indicators. *Neurosci. Res.* **52**, 132–138 (2005).
70. Serrano, A., Haddjeri, N., Lacaille, J., Robitaille, R. & Centre-ville, S. GABAergic Network Activation of Glial Cells Underlies Hippocampal Heterosynaptic Depression. *J. Neurosci.* **26**, 5370–5382 (2006).
71. Anlauf, E. & Derouiche, A. Glutamine synthetase as an astrocytic marker: its cell type and vesicle localization. *Front. Endocrinol. (Lausanne)*. **4**, 144 (2013).
72. Yizhar, O. *et al.* Neocortical excitation/inhibition balance in information processing and social dysfunction. *Nature* **477**, 171–178 (2011).
73. Luis-Delgado, O. E. *et al.* Calibrated forceps: A sensitive and reliable tool for pain and analgesia studies. *J. Pain* **7**, 32–39 (2006).
74. Walf, A. A. & Frye, C. A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. *Nat. Protoc.* **2**, 322–8 (2007).
75. King, T. *et al.* Unmasking the tonic-aversive state in neuropathic pain. *Nat. Neurosci.* **12**, 1364–1366 (2009).
76. Clark, P. J. & Evans, F. C. Distance to Nearest Neighbor as a Measure of Spatial Relationships in Populations. *Ecology* **35**, 445–453 (1954).
77. Millet, L. J., Collens, M. B., Perry, G. L. W. & Bashir, R. Pattern analysis and spatial

distribution of neurons in culture. *Integr. Biol.* **3**, 1167 (2011).

FIGURE TITLES AND LEGENDS

Figure 1. CeL Astrocytes Express Functional Oxytocin Receptors. (a) Overview of CeA fluorescent *in situ* hybridization of OTR mRNA (red) and glutamine synthetase immunostaining (GluSyn, green). (b) High magnification images of cells positive for OTR mRNA and/or GluSyn (double arrows); green arrows point GluSyn positive cells; red arrows point OTR mRNA-positive cells. Scale bars 100 (a) and 10 μ m (b). (c) Proportion of CeL astrocytes (GluSyn positive cells, left) and neurons (NeuN positive cells, right) positive for OTR mRNA (red, hatched) compared to the total number of OTR mRNA positive cells (n astrocytes = 1185, n neurons = 1254, n rats = 3). (d) Experimental rat model for acute brain slice calcium imaging. (e) Experimental scheme of the horizontal CeA slice preparation used, showing C1V1(t/t) expressing OT axons (yellow) arising from PVN and projecting to the CeL. (f-h) Effect of the activation of OT axons in the CeL through λ 542 nm light pulses (10 ms width, 30 Hz, duration 20 s) on calcium transients of CeL astrocytes. (f) (Left) Typical $\Delta F/F_0$ traces; (right) raster plot displaying calcium events per responding astrocyte. (g) (Left) Time course of the calcium events probability per bin of 20s; (right) Δ calcium events probability before and after light-driven activation of CeL OT axons. (h) (Top) Pie chart of the proportion of responsive astrocytes; (bottom) Relative increase of $\Delta F/F_0$ AUC over baseline after light-driven activation of CeL OT axons and maximal peak values reached for responsive astrocytes. Data are expressed as means across slices plus SEM (n slices (n_s) = 6, n astrocytes (n_a) = 37). White circles indicate averages across responding astrocytes per slices. (Statistics in Table S1).

Figure 2. OTR Activation Evokes Astrocytic Calcium Transients in the CeL Astrocyte' Syncytium of Rats and Mice. (a-b) (Top left) Pie charts display the proportion of responsive astrocytes in rats; (middle) images of CeL astrocytes identified through SR101 (red) and corresponding pseudo-color images of OGB1 fluorescence during

baseline and after drug application (stacks of 50 images over 25s of recording). Asterisks indicate astrocytes from which the example $\Delta F/F_0$ traces are shown; (right) typical $\Delta F/F_0$ traces; (histograms) relative increase of $\Delta F/F_0$ AUCs after drug application and maximal peak values reached for responsive astrocytes upon exposition to, from left to right: **(a)** TGOT (400 nM; $n_s = 4$, $n_a = 39$; light blue), TGOT+TTX (1 μ M; $n_s = 22$, $n_a = 182$; dark blue), **(b)** TGOT+TTX+PPADS (50 μ M; $n_s = 6$, $n_a = 59$; orange borders) and TGOT+TTX+CBX (100 μ M; $n_s=8$, $n_a=53$; black borders); histograms for dOVT (1 μ M; $n_s = 3$, $n_a = 34$; red) are not shown, since only 1/34 astrocyte responded. **(c)** Specific deletion of OTRs in mice CeL astrocytes. (Left) Experimental animal model; (middle) example pictures of OTR mRNA (red) and GluSyn labelling in mice injected with rAAV-GFAPP-GFP (top) or rAAV-GFAPP-IRES-Cre vector (bottom); (right) proportion of CeL astrocytes positive for OTR mRNA (red, hatched) compared to total number of GluSyn positive cells (green) (rAAV-GFAPP-GFP vector: n astrocytes = 1340, n mice = 3; rAAV-GFAPP-IRES-Cre vector: n astrocytes = 1561, n mice = 4). **(d)** Histograms displaying relative increase of $\Delta F/F_0$ AUCs after drug application and maximal peak values reached for responsive astrocytes in Control vector (rAAV-GFAPP-GFP) injected mice upon exposure to TGOT (400 nM; $n_s = 13$, $n_a = 35$; light blue). Histograms for data after Cre induced ablation of CeL astrocytes' OTRs ($n_s = 10$) are not shown, since only 62/523 astrocytes showed calcium transients modifications. All values were statistically compared to those of TGOT+TTX: *** $P < 0,001$, Mann-Whitney U test (Statistics in Table S2).

Figure 3. CeL Astrocytes Increased Activity is Sufficient to Recruit the CeL→CeM Neuronal Circuit. **(a)** Experimental rat model. **(b)** Scheme of the experimental setup,

letters indicate in which figure subpart the technique was applied. **(c-e)** (Left) Effect of 3 min long light-evoked activation of C1V1 expressing astrocytes (1 s width, 0.5 Hz) on SICs **(c)** and APs **(d)** frequencies recorded in CeL neurons ($n = 19$ and 10 , respectively), and on **(e)** IPSCs frequencies recorded in CeM neurons ($n = 19$). (Top, right) Example traces of the effect of a 20 s, continuous, λ 542 nm light exposure on the $\Delta F/F_0$ of a C1V1 expressing astrocyte; (bottom, right) typical electrophysiological recordings traces. Patch-clamp data are expressed as averaged frequency plus SEM across cells before, during (and after) light effect; linked white circles indicate individual cell values. $## P < 0.01$, $### P < 0.001$ Wilcoxon signed rank test (Statistics in Table S3).

Figure 4. CeL Astrocytes are Necessary for the CeL→CeM Neuronal Circuit Modulation by OTR Activation. **(a)** Experimental rat model and experiments. (Bottom left) Localization of biocytin-filled astrocytes in the CeA rat brain horizontal slice. (Right) High magnification image. Arrow points to the primary filled cell. Scale bars 400 (left) and 50 μm (right). **(b)** Experimental mouse model and **(c)** scheme of the experimental setup. Letters indicate in which figure subpart the technique was applied: **(a1-3)** Consequences of BAPTA loading (40 mM, 45 min) into CeL astrocytes syncytium on TGOT-induced effect on SICs **(a1)**, $n = 7$ and 8 , dark blue) and APs **(a2)**, $n = 9$ and 9 , light blue) frequencies recorded in CeL neurons, and IPSCs frequencies **(a3)**, $n = 19$ and 17) recorded in CeM neurons. **(b1-3)** (Left) Effects of TGOT (400 nM) on mice injected with GFAPP-GFP vector (control; left) or GFAPP-GFP-IRES-Cre vector (red borders; right) on SICs **(b1)**, $n = 8$ and 5 , dark blue) and APs **(b2)**, $n = 7$ and 11 , blue) frequencies recorded in CeL neurons, and IPSCs frequencies **(b3)**, $n = 27$ and 16) recorded in CeM neurons. (Right) Typical

electrophysiological recordings traces. Patch-clamp data are expressed as averaged frequency plus SEM across cells before, during (and after) drug effect; linked white circles indicate individual cell values. # $P < 0.001$, ### $P < 0.001$ Wilcoxon signed rank test; + $P < 0.05$, +++ $P < 0.001$ Mann-Whitney U test (Statistics in Table S4).

Figure 5. CeL Astrocytes Recruit the CeL→CeM Neuronal Circuit through NMDAR modulation. (a) Experimental rat model. (b) Scheme of the experimental setup. Letters indicate in which figure subpart the technique was applied. (c) Effect of TGOT (400nM; n = 7), TGOT+AP5 (50 μ M; n = 10; orange borders) or TGOT+ifenprodil (3 μ M; n = 10; brown borders) on SICs frequency recorded in CeL neurons. (d) Effect of TGOT (400 nM; n = 9) and TGOT+AP5 (50 μ M; n = 7; orange borders) on APs frequencies recorded in CeL neurons. (e) Effect of DAAO (0.15 U/ml, incubation time > 1h30; purple borders), followed by incubation in D-Serine (20 min, 100 μ M; dark purple borders) on TGOT-induced increase of IPSCs frequencies in CeM neurons (n = 9). Patch-clamp data are expressed as averaged frequency plus SEM across cells before, during (and after) drug effect; linked white circles indicate individual cell values. # $P < 0.001$, ## $P < 0.01$ Wilcoxon signed rank test; + $P < 0.05$ Mann-Whitney U test (Statistics in Table S5).

Figure 6. CeL Astrocytes are Sufficient to Modulate CeA Behavioral Correlates of Comfort and Necessary to their OTR-mediated Modulation. (a) Experimental rat model. TGOT or vehicle were injected 20 min before behavioral tests. rAAV-GFAPp-C1V1(t/t)-mCherry was injected 2 weeks before tests, astrocytes were light-stimulated for

3 minutes with 1 s width pulse at 0,5 Hz immediately prior measurements. **(b)** Experimental mice model. TGOT or its vehicle were administered in OTR-cKO mice previously injected within the CeL either with rAAV-GFAPp-GFP (controls) or rAAV-GFAPp-GFP-IRES-Cre 4 weeks before tests. **(a1, b1)** 4 weeks after the SNI surgery, mechanical pain threshold was assessed on the neuropathic paw before (Ctrl) and after either drugs injections or C1V1 light-driven activation of CeL astrocytes (gray arrow) for sham and SNI animals. **(a2, b2)** Anxiety levels were assessed through measurements of the time spent in the closed arms of the elevated plus maze after drugs injections or C1V1 light-driven activation of CeL astrocytes for sham and SNI animals. **(a3, b3)** Conditioned place preference (CPP) was assessed through measurements of the Δ time spent in the paired chamber before and after pairing. Pairing was realized through drugs injections or C1V1 light-evoked activation of CeL astrocytes for SNI and sham animals. Data are expressed as averages across rats plus SEM. $n = 4-18$ per group (details in Table S6). # $P < 0.001$, ## $P < 0.01$ Wilcoxon signed rank test; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; ANOVA or mixed-design ANOVA followed by posthoc Bonferroni test (Statistics in Table S6).

Figure 7. Oxytocin-dependent Interactions in the CeA. Based on our findings we hypothesize that oxytocin released from axons of PVN oxytocinergic neurons within the CeL activates the oxytocin receptor (OTR)-expressing astrocytes and their neighboring astrocytes inter-connected via gap junctions. Subsequently, the CeL astrocytes release D-serine which gate the activation of CeL interneurons, in turn inhibiting CeM output projection neurons, resulting in anxiolysis and the promotion of a positive emotional state.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

CeL

CeM

bioRxiv preprint doi: <https://doi.org/10.1101/2020.02.25.963884>; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Figure 7

MATERIALS AND METHODS

KEY RESOURCES TABLE

All the reagents used are listed in the Supplementary Table 7

CONTACT FOR REAGENTS AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alexandre Charlet (acharlet@unistra.fr). The requests for viral vectors should be addressed to Valery Grinevich (valery.grinevich@zi-mannheim.de).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals

Animals were housed under standard conditions with food and water available *ad libitum* and maintained on a 12-hour light/dark cycle and all experiments were conducted in accordance with EU rules and approbation from French Ministry of Research (01597.05). For *ex vivo* and *in vivo* experiments, Wistar rats or C5BL/6 mice were used. *Ex vivo* experiments used animals between 18 and 25 days old, except in experiments where rAAVs were injected, in which case animals were between 2 and 6 months old at the time of sacrifice. *In vivo* experiments used 2-month-old animals at the time of the first surgery.

Cloning and Production of rAAV Vectors:

The generation of rAAVs allowing for the specific expression of the protein of interest in OT-cells is described in our previous work⁵. Briefly, the conserved promoter region of 2.6 kb was chosen using the software BLAT from UCSC (<http://genome.ucsc.edu/cgi-bin/hgBlat>), was amplified from BAC clone RP24-388N9 (RPCI-24 Mouse, BACPAC Resources, CHORI, California, USA) and was subcloned into a rAAV2 backbone carrying an Ampicillin-resistance.

To construct the OTp-C1V1(t/t)-TS-mCherry AAV vector we used previously cloned OTp-DIO-GFP-WRE plasmid² equipped with the characterized 2.6 kb OT promoter⁵. In this plasmid the DIO-GFP sequence was replaced by C1V1(t/t)-TS-mCherry from the rAAV CaMKIIa-C1V1(t/t)-TS-mCherry (Addgene, plasmid #35500).

To generate GfaP-C1V1(t/t)-TS-mCherry AAV vector, we replaced the CamKIIa promoter from the rAAV CaMKIIa-C1V1(t/t)-TS-mCherry by the Gfa promoter from the pZac2.1 gfaABC1D-tdTomato (Addgene, plasmid: 44332). The cell type specificity of the rAAV carrying the Gfa promoter was recently confirmed⁶⁷. In analogy, the generation of the GFAP-GFP-IRES-Cre vector was achieved using pZac2.1 gfaABC1D-tdTomato (Addgene, plasmid: 44332). First, the promoter was cloned into a rAAV2 backbone and sticky ends were blunted with EcoR1 and BsrGI. Next, pAAV-CamKIIa-C1V1(t/t)-TS-mCherry was blunted using BamHI and BsrGI. Finally, the pBS-ires cre construct was used and IRES-Cre was inserted into the GFAP-driven vector resulting in the GFAP-GFP-IRES-Cre construct.

Production of chimeric virions (recombinant Adeno-associated virus 1/2; rAAV 1/2) was described in⁵. Briefly, human embryonic kidney cells 293 (HEK293; Agilent #240073) were calcium phosphate-transfected with the recombinant AAV2 plasmid and a 3-helper system. rAAV genomic titers were determined with QuickTiter AAV Quantitation Kit (Cell Biolabs, Inc., San Diego, California, USA) and are $\sim 10^{13}$ genomic copies per ml for all rAAV vectors used in this study.

METHOD DETAILS

Surgeries

Neuropathic Pain Model: Spared Nerve Injury (SNI) Procedure

Animals were randomly separated in two groups to undergo either posterior left hindpaw SNI or sham procedure, with right hindpaw untouched. Animals were anaesthetized using isoflurane at 1.5–2.5%. Incision was made at mid-thigh level using the femur as a landmark and a section was made through the biceps femoris. The three peripheral branches (sural, common peroneal and tibial nerves) of the sciatic nerve were exposed. Both tibial and common peroneal nerves were ligated using a 5.0 silk suture and transected. The sural nerve was carefully preserved by avoiding any nerve stretch or nerve contact⁶⁸. For animals undergoing sham surgery, same procedure was performed but nerves remained untouched. Animals were routinely observed daily for 7 days after surgery and daily tested by the experimenter (Figure S4). Besides observing weight, social and individual behavior, the operated hindpaw was examined for signs of injury or autotomy. In case of autotomy or suffering, the animal was euthanized in respect of the ethical recommendations of the EU. No analgesia was provided after the surgery in order to avoid interference with chronic pain mechanisms and this is in accordance with our veterinary authorization. Suffering was minimized by careful handling and increased bedding.

Stereotaxic Surgery: Injections of rAAV Vectors

Stereotaxic surgery was performed under deep ketamine-xylazine anesthesia, using the KOPF (model 955) stereotaxic system. For specific control of rats CeA astroglial cells, 200 nl of rAAV serotype 1/2 (GFAPp-C1V1TSmCherry, Cloned from plasmids #35500 and 44332, Addgene) were injected bilaterally at the coordinates corresponding to CeL: rostro-caudal: -2.7mm, medio-lateral: 4.2mm, dorso-ventral: -8.0mm (From Paxinos and Watson Atlas). For specific control of

OT neurons, 200 nl of rAAV serotype 1/2 (OTp-C1V1TSmCherry or OTp-ChR2mCherry) were injected bilaterally at the coordinates corresponding to each hypothalamic OT nuclei. PVN: rostro-caudal: -1.8mm; medio-lateral: +/-0.4mm; dorso-ventral: -8.0mm; SON: rostro-caudal: -1.4mm; medio-lateral: +/-1.6mm; dorso-ventral: -9.0mm; AN: rostro-caudal: -2mm; medio-lateral: +/-1.2mm; dorso-ventral: -8.5mm (From Paxinos and Watson Atlas). For specific deletion of OTR in mice CeL astrocytes, 280 nl of rAAV serotype 1/2 (GFAPp-GFP-IRES-Cre) were injected bilaterally at the coordinates corresponding to CeL: rostro-caudal: -2.7mm, medio-lateral: 4.2mm, dorso-ventral: -8.0mm (From Paxinos and Watson Atlas) in OTR-ckO mice.

Stereotaxic Surgery: intra-CeL Cannulae

Cannulae Implantation. Animals were bilaterally implanted with guide cannulae for direct intra-CeL infusions. As guide cannulae we used C313G/Spc guide metallic cannulae (Plastics one, VA, USA) cut 5.8 mm below the pedestal. For this purpose, animals were deeply anesthetized with 4% isoflurane and their heads were fixed in a stereotaxic frame. The skull was exposed and two holes were drilled according to coordinates that were adapted from brain atlas (rat, 2.3 mm rostro-caudal; 4 mm lateral; 7.5 mm dorso-ventral relative to bregma; mice, 1.4 mm rostro-caudal; 2.6 mm lateral; 4.3 mm dorso-ventral relative to bregma) by comparing the typical bregma-lambda distance with the one measured in the experimental animal. Two screws were fixed to the caudal part of the skull in order to have an anchor point for the dental cement. Acrylic dental cement was finally used to fix the cannulae and the skin was sutured. In case of long lasting experiments (neuropathy-induced anxiety) with a cannula implantation at distance of the behavioral assay (> 4 weeks), cannulae were sometimes lost or cloaked, and concerned animals therefore excluded from testing.

Drugs Infusions. We used bilateral injections of 0.5 µl containing either vehicle (NaCl 0.9%) or oxytocin agonist TGOT (1 µM) dissolved in NaCl 0.9%. For this procedure two injectors (cut to fit 5.8 mm guide cannulae protruding 2 to 2.5 mm beyond the lower end of the cannula in older animals and 1.8 mm in 3-4 week old rats) were bilaterally lowered into the guide cannula, connected via polyten tubing to two Hamilton syringes that were placed in an infusion pump and 0.5 µl of liquid was injected in each hemisphere over a 2-minute-period. After the injection procedure, the injectors were kept in place for an additional minute in order to allow a complete diffusion of liquid throughout the tissue. Rats were subsequently left in the home cage for 15 minutes to recover from the stress of the injection and then handled for mechanical pain threshold or anxiety assessment. Animals that received TGOT injections for the first experiment (mechanical sensitivity assessment) were switched to the vehicle injected groups for the elevated plus maze experiment.

Stereotaxic Surgery: intra-CeL Optical Fiber

Optical Fiber Implantation. Sham and rAAVs injected animals both underwent a single surgical procedure in which after vector injection or no injection for sham, optical fibers designed to target the CeL were implanted and firmly maintained on the skull using dental cement. See “**cannulae implantation**” for the surgical procedure. Implantable optical fibers were homemade using optical fiber cut at appropriate length (FT200EMT, Thorlabs, NJ, USA) inserted and glued using epoxy based glue in ferrules (CFLC230-10, Thorlabs, NJ, USA).

Horizontal and Coronal Slices

Slices Preparations. In all cases, animals were anaesthetized using ketamine (Imalgene 90 mg/kg) and xylazine (Rompun, 10 mg / kg) administered intra-peritoneally. Transcardial perfusion was then performed using one of the following artificial cerebro-spinal fluids (ACSFs) dissection solutions. For animals between 18 and 25 days old, an ice-cold sucrose based dissection ACSF was used containing (in mM): Sucrose (170), KCl (2.5), NaH₂PO₄ (1.25), NaHCO₃ (15), MgSO₄ (10), CaCl₂ (0.5), HEPES (20), D-Glucose (20), L-ascorbic acid (5), Thiourea (2), Sodium pyruvate (3), N-acetyl-L-cysteine (5), Kynurenic acid (2). For animals between 2 and 6 months old, an ice-cold NMDG based ACSF was used containing (in mM): NMDG (93), KCl (2.5), NaH₂PO₄ (1.25), NaHCO₃ (30), MgSO₄ (10), CaCl₂ (0.5), HEPES (20), D-Glucose (25), L-ascorbic acid (5), Thiourea (2), Sodium pyruvate (3), N-acetyl-L-cysteine (10), Kynurenic acid (2). In both cases, pH was adjusted to 7.4 using either NaOH or HCl, this after bubbling in 95% O₂-5% CO₂ gas, bubbling which was maintained throughout the duration of use of the various ACSFs. Those ACSFs formulae were based on the work of⁶⁹. Following decapitation, brain was swiftly removed in the same ice-cold dissection ACSFs as for transcardial perfusion, and 350 µm thick horizontal slices containing the CeA obtained using a Leica VT1000s vibratome. For experiments in Figure S1E, coronal slices of the same thickness containing the PVN were used. Upon slicing, brain slices were hemisected and placed, for 1 hour minimum before any experiments were conducted, in a room tempered holding chamber, containing normal ACSFs. For 2 to 6 month old animals, slices were first let for 10 minutes in 35°C NMDG ACSF before placing them in the holding chamber at room temperature. Normal ACSF, also used during all *ex vivo* experiments, is composed of (in mM): NaCl (124), KCl (2.5), NaH₂PO₄ (1.25), NaHCO₃ (26), MgSO₄ (2), CaCl₂ (2), D-Glucose (15), adjusted for pH values of 7.4 with HCL or NaOH and continuously bubbled in 95% O₂-5% CO₂ gas. All ACSFs were checked for osmolality and kept for values between 305-310 mOsm/L. In electrophysiology or calcium imaging experiments, slices were transferred from the holding chamber to an immersion recording chamber and superfused at a rate of 2 ml/min with normal ACSFs unless indicated otherwise.

Drug Application. OTR agonists were bath applied through a 20s long pumping of agonist solution, corresponding to several times the volume of the recording chamber. Other drugs (antagonists, TTX, channel blockers etc.) were applied for at least 20 minutes in the bath before performing any experiments. BAPTA (or BAPTA-free solution for controls) loading of CeL astrocytes was realized following⁷⁰ protocol. Two distant CeL astrocytes per slice (label with SR101, 1 µM) were patched in whole cell configuration and voltage steps were applied (2 Hz, Δ40 mV) to help loading the BAPTA contained in the patch pipette (in mM): MgCl₂ (1), NaCl (8), ATP (2) GTP (0.4) HEPES (10), BAPTA (40) and osmolality checked to be between 275-285 mOsm/l. The whole cell configuration was maintained during 45 min to allow BAPTA diffusion into the astrocytes syncytium.

Calcium Imaging and Identification of Astrocytes

To identify astrocytes, SR101 (1 μ M) was added to ACSF in a culture well and slices were incubated for 20 minutes at 35°C. The specificity of SR101 labelling to astrocytes of the CeL was verified through patch-clamp experiments, the results of which can be found in Figure S2a-c. After SR101 loading, the synthetic calcium indicator OGB1 or Rhod-2 was bulk loaded following an adapted version of the method described previously⁶⁹ reaching final concentrations of either 0.0025 % (~20 μ M) for OGB1 or 0.0025 % (~20 μ M) for Rhod-2, 0.002% Cremophor EL, 0.01 % Pluronic F- 127 and 0.5% DMSO in ACSF, and incubated for 45 to 60 minutes at 38°C. Upon incubation time, slices were washed in ACSF for at least an hour before any recording was performed. Astrocytes recorded for this study were then those co-labeled, in rats for SR101 and OGB1 and in mice for GFP and Rhod2. The spinning disk confocal microscope used to perform astrocyte calcium imaging was composed of a Zeiss Axio examiner microscope with a 40x water immersion objective (numerical aperture of 1.0), mounted with a X-Light Confocal unit – CRESTOPT spinning disk. Images were acquired at 2Hz with either a Rolera em-c² emCCD or an optiMOS sCMOS camera (Qimaging, BC, Canada). Cells within a confocal plane were illuminated for 100 to 150 ms for each wavelength (SR101 and Rhod-2: 575 nm, OGB1 and GFP: 475 nm) using a Spectra 7 LUMENCOR. The different hardware elements were synchronized through the MetaFluor software (Molecular Devices, LLC, Ca, USA) which was also used for online and offline quantitative fluorescence analysis. Astrocytic calcium levels were measured in hand drawn ROIs comprising the cell body plus, when visible, proximal processes, without distinction. In all recordings, the Fiji rolling ball algorithm was used to increase signal/noise ratio.. Absolute $[Ca^{2+}]_i$ variation were estimated as changes in fluorescence signals over the baseline ($\Delta F/F$). Baseline was established for each ROI as the average fluorescence over all pictures. To take into account micro-movements of the specimen on long duration recordings, the $\Delta F/F$ values were also calculated for SR101 / GFP and subsequently subtracted to the ones of OGB1 / Rhod2, except in the case of Figure 1f-h, where astrocytes were identified through SR101 fluorescence after the recordings, to avoid unwanted stimulation of the C1V1(t/t) opsin. On this last case, recordings in which movements / drifts were visible were discarded. Bleaching was further corrected by fitting a linear regression on the overall $\Delta F/F$ trace for each ROI, which values were then subtracted to the $\Delta F/F$. Upon extraction of data, calculations and corrections of $\Delta F/F$ for each astrocyte, the area under the curve before and after OTR agonists' application (or light pulse for optogenetics experiments) were calculated and proportionally corrected relative to the different baseline and after stimulation recording durations. An astrocyte was considered as being responsive if the relative ratio of AUCs after drug/light application over baseline was higher or equal to a 20% increase. The relative AUCs ratios values of responding astrocytes were used for quantitative analysis and called "relative AUC increase", and in corresponding histograms the coordinate indicated as a 0 corresponds to a ratio of 1 (meaning neither increase nor decrease of the AUC). The maximal peak reached after drug/light application was also measured in responsive cells and used in quantitative analysis shown in various figures. Data were averaged across all responding astrocytes per slice, which were used as the statistical unit. For the response probability, calcium events were detected as an increases of fluorescence > 5% with a rising slope > 0,025 and a minimum inter-peak distance of 10 seconds. Then, the response probability was calculated as the number of astrocyte with a least 1 calcium event per time bin (30s) divide per the number of astrocyte in each recording. Image J software was also used on SR101 / OGB1 pictures to

produce illustrative pictures. Finally, all calcium imaging experiments were conducted at controlled room temperature of 26°C.

Electrophysiology

Whole cell patch-clamp recordings of CeL neurons, CeL astrocytes and CeM neurons were visually guided by infrared oblique light visualization of neurons and completed by SR101 fluorescence observation for astrocytes. Patch-clamp recordings were obtained with an Axon MultiClamp 700B amplifier coupled to a Digidata 1440A Digitizer (Molecular Devices, CA, USA). Borosilicate glass electrodes ($R = 3.5 - 7 \text{ M}\Omega$) with inner filament (OD 1.5 mm, ID 0.86 mm; Sutter Instrument, CA USA) were pulled using a horizontal flaming/brown micropipette puller (P97; Sutter Instrument, CA, USA). Recordings were filtered at 2 kHz, digitized at 40 kHz and stored with the pClamp 10 software suite (Molecular Devices; CA, USA). Analysis of patch-clamp data were performed using Clampfit 10.7 (Molecular Devices; CA, USA) and Mini analysis 6 software (Synaptosoft, NJ, USA) in a semi-automated fashion (automatic detection of events with chosen parameters followed by a visual validation).

Whole-Cell Recording of CeL Neurons and Astrocytes. Recording pipettes were filled with an intracellular solution containing (in mM): KMeSO_4 (125), CaCl_2 (2), EGTA (1), HEPES (10), ATPNa_2 (2), GTPNa (0.3). The pH was adjusted to 7.3 with KOH and osmolality checked to be between 290-295 mOsm/l, adjusted with sucrose if needed. All neurons were held at a membrane potential of -65 mV, astrocytes -80 mV. Series capacitances and resistances were compensated electronically throughout the experiments using the main amplifier. For SICs measurements in CeL neurons (Figure 3, 4, S3, S4), whole cell recordings were conducted in a Mg^{2+} free ACSF, also containing bicuculin (10 μM) and TTX (1 μM) as in²⁷. Currents were categorized as SIC when their rise time (10% to 90%) and decay tau were strictly superior to 8 and 30 ms, respectively. Average SICs frequencies per cell was calculated over 10 minutes periods during basal condition and 10 minutes periods after the bath application of TGOT. CeL neurons were classified as TGOT-responsive when the average SIC frequency was increased by at least 30% after TGOT application when compared to its baseline.

Whole-cell Recording of CeM Neurons. Pipettes were filled with an intracellular solution containing (in mM): KCl (150), HEPES (10), MgCl_2 (4), CaCl_2 (0.1), BAPTA (0.1), ATP Na salt (2), GTP Na salt (0.3). pH was adjusted to 7.3 with KOH and osmolality checked to be between 290-295 mOsm/L, adjusted with sucrose if needed. All cells were held at a membrane potential of -70 mV. Series capacitances and resistances were compensated electronically throughout the experiments using the main amplifier. Average events frequencies per cell were calculated on 20s windows, chosen for TGOT or light stimulation during maximal effect, as determined by the visually identified maximal slope of the cumulative plot of the number of events. CeM neurons were classified as TGOT-responsive when the average IPSCs frequency was increased by at least 20% during at least 10s and up to 500s after TGOT application when compared to baseline average frequency. Baseline and recovery frequencies were measured respectively at the beginning and end of each recording. All patch-clamp experiments were conducted at room temperature.

Immunohistochemistry and *in situ* Hybridization

In situ Hybridization for OTR mRNA in Rat CeL. The probe for OTR mRNA was *in vitro* transcribed from a 902-bp fragment containing 133-1034 bases of the rat OTR cDNA (NCBI Reference Sequence: NM_012871.3) subcloned into pSP73 Vector (Promega). The digoxigenin (DIG)-labeled antisense and sense RNA probe from the linearized *oxtr* cDNA template was synthesized using DIG RNA Labeling Kit (SP6/T7) (Roche Diagnostics). Sections containing 2 consecutive sections of the CeL (corresponding to Bregma: 2.5) were processed for fluorescent *in situ* hybridization (FISH). Rats were transcardially perfused with PBS followed by 4% PFA. Brains were dissected out and post fixed overnight in 4% PFA at 4 °C with gentle agitation. 50 µm vibratome sections were cut, collected and fixed in 4% PFA at 4°C overnight. The free-floating sections were washed in RNase-free PBS, immersed in 0.75% glycine in PBS, treated with 0.5 µg/ml proteinase K for 30 min at 37 °C, acetylated with 0.25% acetic anhydride in 0.1 M triethanolamine, and then hybridized with DIG-labeled RNA probe overnight at 65 °C. After RNase treatment and following intensive wash, the hybridized DIG-labeled probe was detected by incubation with Anti-Digoxigenin-POD (1:200; 11207733910; Roche Diagnostics) for 3 days at 4 °C. Signals were developed with tyramid signal amplification method. Rhodamine-conjugated tyramide was synthesized by coupling NHS-Rhodamine (Pierce Biotechnology, Thermo Fisher Scientific) to Tyramine-HCl (Sigma-Aldrich) in dimethylformamide with triethylamine. For the quantification of OTR mRNA-positive astrocytes, all confocal images were obtained using the same laser intensities and processed with the same brightness / contrast settings in Adobe Photoshop. Since the *in situ* signal for the OTR mRNA in astrocytes was weak, we first calculated the average intensity (signal intensity of all pixels divided by the total number of pixels) of the rhodamine-stained OTR mRNA signal for each individual section containing the CeL. Next, we calculated the standard deviation for each individual confocal image based on the intensity of all pixels comprising the image. We defined the threshold for OTR mRNA-positive astrocytes: If more than 1/4 of all pixels comprising an astrocyte soma displayed a signal intensity exceeding the average background intensity by more than 4-times the standard deviation, the astrocytes were considered as OTR mRNA-positive.

Astrocytes Markers. The aldehyde dehydrogenase 1 antibody is a commonly used marker for glial cells, including astrocytes. Therefore, we used the ALDH1L1 for immunohistochemistry in our initial experimental studies (Figure S1, S3). However, due to inconsistencies in staining quality as a result of batch-dependent antibody properties, especially in combination with the OTR mRNA FISH, we decided to employ Glutamine Synthetase (GluSyn, Figure 1a). GluSyn is a commonly used glial marker⁷¹, which stains astrocyte cell bodies, faint processes and even astrocytes not expressing GFAP. Using GluSyn, we achieved consistent results in combination with our OTR mRNA FISH.

Glutamine Synthase, ALDH1L1 Colocalization with OTR mRNA in Rat CeL. After development and washing steps the sections were stained with antibodies against glutamine synthase (mouse monoclonal, 1:500, ref: MAB302, MerckMilipore), ALDH1L1 (rabbit polyclonal, 1:500, ref: ab87117, abcam), in PBS and kept at 4°C on a shaker in a dark room overnight. After intensive washing with PBS, sections were stained with the respective secondary antibodies AlexaFluor488 (goat anti-mouse, 1:1000, ref: A11001, life technologies) and AlexaFluor680 (goat

anti-mouse, 1:1000, ref: A27042, ThermoFischer Scientific) for 2 hours at RT. Following intensive washing with PBS, sections were mounted using Mowiol.

Double in situ Hybridizations for OTR mRNA and GFAP mRNA in Mice CeL. Fluorescent *in situ* hybridization (FISH) in Figure S1 was performed on 25- μ m cryostat-cut coronal sections prepared from fresh-frozen mouse brain (male C57BL/6J, P22). After extraction, brains were immediately frozen in Tissue-Tek O.C.T. compound and stored at -80 degrees Celsius. ISH was performed according to the manufacturer's instructions (Advanced Cell Diagnostics) for Fresh Frozen RNAscope Multiplex Fluorescent Assay. Treatment of amygdala containing sections were adjusted with the 3-plex negative control and then coexpression of OTR and GFAP examined using ACD designed target probes as well as the nuclear stain DAPI. Single plan images were collected with an upright laser scanning microscope (LSM-710, Carl Zeiss) using a 40x-objective with keeping acquisition parameters constant between control and probe treated sections.

Specific deletion of OTRs in CeL astrocytes. To specifically ablate OTRs in CeA astrocytes, transgenic cKO mice, in which *loxP* sites flank the OTR coding sequence (Lee et al., 2008), received bilateral injections (280 nl) of rAAV-GFAP-GFP-IRES-Cre. Following four weeks of expression of the viral proteins, mice were transcardially perfused with 1x PBS and 4% PFA. Brain sections were used for FISH (OTR mRNA) and IHC (GluSyn) to verify the validity of the approach. Representative images and quantifications are provided in Figure 2c.

AAV-Gfa-C1V1TsmCherry Specificity. After 3 weeks of vector expression in the brain, rats were transcardially perfused with 4% paraformaldehyde solution. Tissue blocks, containing CeA were dissected from the fixed brain and Vibratome-cut into 50 μ m thick free-floating sections. After several rinse steps sampled sections were blocked with 5% NGS in PBS and incubated for 48 h at 4°C with polyclonal rabbit anti-ALDH1L1 antibody (1:500, Abcam) in 1% Triton-PBS buffer, containing 0,1 % NGS. Appropriate secondary antibody (AlexaFluor488 conjugated goat anti-rabbit (1:1000, LifeTechnologies) was used for further antigene detection. Intrinsic mCherry fluorescence of vector-expressing cells was strong enough to detect them in the tissue without any additional antibody enhancement. The immunolabeled sections were mounted onto Superfrost slides, cover-slipped with Mowiol, analyzed and documented using LEICA SP5 confocal microscope.

Biocytin Filling of Astrocytes. In the lateral part of the central amygdala slices visualized with infrared-differential contrast optics, astrocytes were identified by their morphological appearance and the absence of action potentials in response to depolarizing current injections. Cells were patched with pipettes filled with (in mM) 110 K-gluconate, 30 KCl, 4 ATP-Mg, 10 phosphocreatine, 0.3 GTP, and 10 HEPES (pH: 7.3; 310 mOsm). Concentration of biocytin was 2 mg/ml. After obtaining whole-cell configuration astrocytes were hold at -80 mV and typical filling time was 30 minutes. Then the pipettes were carefully retracted and slices were incubated for additional 20 minutes in the oxygenated ACSF before fixation. Only one cell was filled per slice. Slices with filled cells were immersion-fixed at 4°C for 5 days in 4% PFA-PBS solution. Next, the slices were flat-embedded in 6% Agar-PBS, areas of interest were cut out of, re-embedded onto the Agar block and Vibratome-cut into 80 μ m thick free-floating sections. The sections then were incubated with Avidin conjugated to Alexa Fluor488 (1:1000) (Thermo Fisher) in 1% Triton-PBS at 4°C, washed

in PBS, mounted and cover-slipped. The tissue was analyzed and images taken at Leica TCS SP5 Confocal Microscope.

Optogenetics

Ex vivo. To elicit evoked activation of OT axons in combination with CeL or CeM neurons patch-clamp, we used ChR2 expression in OT cells, as in⁵. Optical blue-light illumination of the CeL oxytocinergic axons expressing ChR2 was performed using light source XCite® 110LED from Excelitas Technologies through a GFP filter, controlled with Clampex driven TTL pulses for 20s at 30Hz with 10ms long pulses. To elicit light-evoked activation of OT axons in combination with astrocyte calcium imaging, or to elicit intracellular calcium increase in astrocytes, we used C1V1(t/t), a ChR1/VChR1 chimera with the combined mutations E122T/E162T (for more details, see⁷². Optogenetic green light stimulation of C1V1(t/t) in *ex vivo* experiments was performed using either the Spectra 7 LUMENCOR (λ542 nm) or light source X-Cite® 110LED from Excelitas Technologies through a Cy3 filter, controlled via MetaFluor or Clampex driven TTL pulses, respectively.

In vivo. Animals were habituated to the fixation of an optical fiber on the ferrule without light stimulation for one week before the experiment. In all cases, optical fibers were attached to the ferrules using an adapter (ADAF2, Thorlabs, NJ, USA) and animals let free to move in a typical home cage for the duration of the stimulation. Implanted optical fibers were connected to two lasers (LRS-0532-GFM-00100-03 LaserGlow 532nm DPSS Laser System) and the output power adjusted to correspond to 20 to 30 mW measured at the tip of 200 μm diameter fibers similar to the one implanted. Stimulation of 500 ms duration at a frequency of 0.5Hz were given for 3 min.

Behavior

Mechanical Sensitivity Assessment. In experiments with rats, we used a calibrated forceps (Bioseb, Chaville, France) previously developed in our laboratory to test the animal mechanical sensitivity⁷³. Briefly, the habituated rat was loosely restrained with a towel masking the eyes in order to limit stress by environmental stimulations. The tips of the forceps were placed at each side of the paw and a graduate force applied. The pressure producing a withdrawal of the paw, or in some rare cases vocalization, was considered as the nociceptive threshold value. This manipulation was performed three times for each hind paw and the values were averaged as being the final nociceptive threshold value. In experiments with mice, we used von Frey filaments tests. Mechanical allodynia (a symptom of neuropathic pain) was tested using von Frey hairs and results were expressed in grams. Tests were performed during the morning starting at least 2 h after lights on. Mice were placed in clear Plexiglas boxes (7 cm x 9 cm x 7 cm) on an elevated mesh floor. Calibrated von Frey filaments (Bioseb) were applied to the plantar surface of each hindpaw until they just bent in a series of ascending forces up to the mechanical threshold. Filaments were tested five times per paw and the paw withdrawal threshold (PWT) was defined as the lower of two consecutive filaments for which three or more withdrawals out of the five trials were observed.

Elevated Plus Maze. Following protocol from⁷⁴, the arena is composed of four arms, two open (without walls) and two closed (with walls; rats 30 cm high; mice 15 cm high). Arms are 10 cm wide, 50 cm long and elevated 50 cm off the ground for rats and 5 cm wide, 30 cm long and elevated 40 cm of the ground for mice. Two lamps with intensity adjustable up to 50 watts were positioned on the top of the maze, uniformly illuminating it. Animals were video tracked using a video-tracking systems (Ethovision Pro 3.16 Noldus, Wageningen, Netherlands and Anymaze, Stoelting Europe, Ireland). After each trial, the maze was cleaned with 70% ethanol and dry with paper towel. Twenty minutes after intracerebral injections or directly after optical stimulation, the animal was let free at the center of the plus maze, facing the open arm opposite to where the experimenter is, and was able to freely explore the entire apparatus for six minutes. Total time and time spend in closed and open arms were recorded in seconds and the percentage of time spent in closed arms was calculated as a measure of anxiety. As internal control, the total distance traveled during the test period was quantified and compared between all different groups (Figure S6a2-b2). Animals falling from the apparatus during the test, freezing more than 50% of the total time, or with cannulae/optic fiber issues, were removed from the analysis.

Conditioned Place Preference. The device is composed of two opaque conditioning boxes (rats: 30x32 cm; mice: 22x22 cm) and one clear neutral box (30x20 cm) Animals were video tracked using a video-tracking system (Anymaze, Stoelting Europe, Ireland). After each trial, the device was cleaned with a disinfectant (Surfa'Safe, Anios laboratory). Based on⁷⁵, all rats underwent a 3 days habituation period during which they were able to freely explore the entire apparatus for 30 min. On the day 3, behavior was record for 15min to verify the absence of pre-conditioning chamber preference. The time spend in the different compartment were measured and paired compartment was chosen as the compartment in which rat spent the less time during the 3rd day of habituation. On day 4, animals were placed the morning in one compartment for 15 min with no stimulation (unpaired box). Four hours after, the animal were placed 15min in the opposite box (paired box) and CeL astrocyte expressing C1V1 vector were optogenetically stimulated (3 min - 500ms light pulse at 0.5 Hz - λ 542nm) or TGOT micro-infused through intracerebral cannulae. On day 5, the animals were place in the CPP box and allowed to freely explore the entire apparatus during 15min. As internal control, the total distance traveled during the test period was quantified and compared between all different groups (Figure S6). Rats falling spending more than 80% of the total time in a single chamber before the conditioning, or with cannulae/optic fiber issues, were removed from the analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical Analysis

All parametrical statistical tests presented in figure captions were performed following correct verification of the assumptions on the distribution of data, and if not non-parametric tests were used. Tests were performed using either SPSS 23 (IBM) or statview 5 (SAS institute Inc.). All values, group compositions and statistical tests for each experiment and figure panel are detailed in Supplementary Tables 1-6.

Spatial Distribution Analysis of Astrocytes within the CeL.

For the analysis of spatial distribution of astrocytes within the CeL, confocal images were analyzed and all OTR+ astrocytes were manually marked. A separate image with the location of identified astrocytes in the CeL was exported for spatial distribution analysis. The coordinate's points of OTR+ astrocytes (events) were extracted with custom-written MATLAB (MathWorks) script and the centroid of each event was calculated with the function *regionprops*. The univariate first-order nearest neighbor (NN) test (Clark-Evans statistic) was derived from the distance to the closest event for each data point in the image. The test estimates the departure of the observed NN distances from those expected under a null model of complete spatial randomness (CSR; a homogeneous Poisson process). We calculated the mean NN distance for all events in each image as:

$$\bar{r}_A = \frac{\sum r}{N}$$

where r is the distance from a given event to its nearest neighbor, and N is the number of events in a given population. The ratio $R = \frac{\bar{r}_A}{\bar{r}_E}$ is the observed mean NN distance by mean distance which would be expected if this population was distributed randomly. In a random distribution $R = 1$. The values of R can vary between 0 (maximum aggregation or *clustering*) and 2.1491 (maximum spacing or *uniformity*). For details see^{76,77}. Thus, R values are indicative of uniform, random, and clustered patterns of point distribution. To evaluate the significance of R , it is possible to calculate the standard variate of the normal curve, namely the c-score:

$$c = \frac{\bar{r}_A - \bar{r}_E}{\sigma_{\bar{r}_E}}$$

where $\sigma_{\bar{r}_E}$ is the standard error of the mean distance to NN in a randomly distributed population with the same number of events as the observed population. The c value 1.96 represents the 5% level of significance for a two-tailed test. We calculated the mean NN distance for 12 randomly selected images, R , and the c-score for image of the CeL (Figure S1b): Only in two images the c-score was equal to or greater than 1.96, therefore only in two of the images it was possible to reject the null hypothesis of randomly distributed population (Statistics in Table S1).

SUPPLEMENTAL INFORMATION

Figure S1. (a) (Left) FISH overview of CeA hybridized with OTR mRNA (green), counterstained with polyclonal anti-ALDH1L1 antibody (red). (Middle) High magnification image of cells positive for both OTR mRNA and ALDH1L1 (double arrows); green arrows point OTR mRNA-positive cells; red arrows point ALDH1L1-positive cells. Scale bar 400 (Left) and 50 μ m (Middle). (Right) Quantification of ALDH1L1-positive cells containing OTR mRNA signaling. n astrocytes=450; n rats=3 (b) Spatial distribution analysis of astrocytes within the CeL (R and c-score) demonstrating the random distribution of OTR positive astrocytes. (c) RNAscope *in situ* hybridization showing GFAP (red) and OTR (green) expressing cells in mice CeA. Merged images include DAPI stain (blue). (Bottom) Negative control probe targeting the bacterial gene DapB. Scale bar 10 μ m. (d) Combination of FISH and IHC showing co-localization of GluSyn (top left), NeuN (bottom) and both markers (top right) with OTR mRNA in mice. 1254 NeuN-positive neurons and 1185 GluSyn-positive astrocytes. We detected 67.8 % OTR-positive neurons, mostly in the dorsal part the the CeL, and 12.7 % OTR-positive astrocytes. Scale bars 100 μ m, 10 μ m. (e) (Left) C1V1(t/t)-mCherry expressing oxytocin neurons of the PVN in which (Right) λ 542nm light exposure induced depolarizing currents, enabling precise spiking control as measured in whole cell patch-clamp. st: stria terminalis. (Statistics and numbers in Table S1).

Figure S2. (a) Typical confocal image of CeL astrocytes co-labeled with SR101 and OGB1. Scale bar 20 μ m. (b) (Left) Pseudo-color pictures of an SR101 positive cell identified as an astrocyte compared to neurons identified under oblique infrared light, Scale bar 10 μ m. (Middle) Electrophysiological properties of patched SR101+ (red, n=84) and SR101- cells (grey, n=21). (Right) Typical responses to 20pA current steps of a SR101+ (red) and a SR101- cells (black) (c) CeL SR101 positive cell filled with biocytin through whole cell patch-clamp (green) lacks NeuN signal (Blue). Scale bar 50 μ m. (d) (Up) Pie charts of the proportion of TGOT+TTX responsive astrocytes and their (bottom, histograms) relative increase of $\Delta F/F$ AUC after drugs application and maximal peak values upon exposition to PPADS (50 μ M) + Suramin (75 μ M) + A438079 (1 μ M) (n_s = 6, n_a = 289). Data are expressed as mean across slices plus SEM. White circles indicate average across responding astrocytes per slice. * P <0.05, independent samples Student's t-test, + P <0.05, ++ P <0.01, +++ P <0.001 independent samples Mann-Whitney U test, # P <0.05 Wilcoxon signed rank test (Statistics in Table S2). White circles represent the average across responding astrocytes per slice. (e) Immunohistochemical staining for glutamine synthetase (GluSyn; *i.e.* astrocytes; blue), GFP (green) and Cre recombinase (red). (Right picture) Overview of the CeA, displaying correct viral targeting of the CeL subdivision. Efficiency: Over 1001 GluSyn positive cells, 561 were also GFP positive, indicating an efficiency of 56 $\pm$ 4.9%). Specificity: we counted a total of n=977 GFP-positive cells, 940 of which were positive for GluSyn (96.2 $\pm$ 2.1%). None of the GFP or Cre signals were detected in NeuN positive cells (0 out of n = 850, 3 mice, not shown). Finally, 99.82 $\pm$ 0.2% of GluSyn-positive astrocytes contained GFP signal were Cre-positive (n = 1001). (f) Immunohistochemical analysis of OTR expression in NeuN-positive neurons of the CeL revealed no difference in OTR levels between control and GFAP-Cre injected animals; 89.3 $\pm$ 4.8% (n = 989, n = 4 mice) and 86.0 $\pm$ 3.7% (n = 1204, n = 4 mice) respectively. (Statistics and numbers in Table S2).

Figure S3. (a) (Left) Immunohistochemistry image shows CeL cells transfected with rAAV-Gfap-C1V1TSmCherry with co-labeling for ALDH1L1. White arrow shows one cell expanded in insets. Scale bars 25 and 10 μm (insets). (Right) Quantification of the efficiency and specificity of transduction of C1V1 in CeL astrocytes. rAAV GFAP-C1V1-mCherry vector was injected into rat CeA (bilaterally, 300nl). Specificity: we counted a total of $n=323$ mCherry-positive cells, 318 of which were positive for ALDH1L1 ($98.5\pm0.8\%$). None of the analyzed cells were positive for NeuN. Efficiency: Over 517 ALDH1L1 positive cells, 318 were also mCherry positive, indicating an efficiency of $62.3\pm3.5\%$. (b) (Top) Pie chart showing the proportion CeL neurons displaying SICs and (bottom) their electrophysiological properties, measured in 0 Mg^{2+} ACSF with TTX ($1\text{ }\mu\text{M}$) and Bicuculline ($10\text{ }\mu\text{M}$) ($n = 15$). (c, d) Effect of CeL astrocytes BAPTA loading on 3 min long light-evoked activation of C1V1 expressing CeL astrocytes (1 s width, 0.5 Hz) on APs (c) and IPSCs (d) frequencies recorded in CeL and CeM neurons ($n = 12$ and 9 , respectively). In (b, c, d) data are expressed as averages plus SEM and white circles represents SICs electrophysiological properties averaged per cell. (Statistics and numbers in Table S3).

Figure S4. (a) Effect of TGOT on SICs properties in presence of 0 Mg^{2+} , TTX ($1\mu\text{M}$) and Bicuculline ($10\text{ }\mu\text{M}$) ($n = 6$). Data are expressed as averages plus SEM and white circles represents SICs electrophysiological properties averaged per cell before and after TGOT application. (Statistics and numbers in Table S4).

Figure S5. (a) (Top) pie chart of the proportion of TGOT+TTX responsive astrocytes and (bottom) relative increase of $\Delta F/F$ AUC after TGOT application and maximal peak value following exposition to AP5 ($50\text{ }\mu\text{M}$; $n_s = 4$, $n_a = 35$). (b) (Left) Effect of double (20 min apart) application of TGOT on IPSCs frequencies in CeM ($0.4\text{ }\mu\text{M}$ $n = 7$). (Right) dOVT ($1\text{ }\mu\text{M}$; $n = 3$) prevents the effect of TGOT on IPSCs frequencies in CeM. (c) Effect of AP5 ($50\text{ }\mu\text{M}$, $n = 7$) or DCKA ($10\text{ }\mu\text{M}$, $n = 12$) on TGOT-induced increase in IPSCs frequencies in CeM neurons. (d) DNQX ($25\text{ }\mu\text{M}$; $n = 8$) effect on TGOT induced increase in IPSCs frequencies in CeM neurons. In (b,c,d) Data are expressed as averages plus SEM and white circles represent individual cell data. * $P<0.05$, ** $P<0.01$, independent samples (calcium-imaging) or paired (patch-clamp) Students's t-test (Statistics and numbers in Table S5).

Figure S6. (a) Experiments in rat model. 30 days post surgeries time course of mechanical pain threshold evolution across sham and SNI groups. (b) Experiments in mice model. (a1, b1) Mechanical pain threshold was also assessed on the non-injured paw of SNI (left) and its equivalent in Sham (right) groups. TGOT or its vehicle, or astrocytes light-evoked activation of C1V1, were administered in the CeL and mechanical pain threshold assessed again at different time points. (a2, b2) Locomotion was assessed through measurement of the distance travelled during the length of the elevated plus maze experiment, after administration of the different treatments. (a3, b3) Locomotion was assessed through measurement of the distance travelled during the time of the conditioned place preference experiment, after administration of the different treatments. (a4) TGOT effect on CeM neurons IPSCs frequencies is unchanged between Sham ($n = 16$) or SNI ($n = 16$) rats. Data are expressed as average plus SEM and white circles represent

individual cell data. Mixed design ANOVA followed by posthoc Bonferroni tests (Statistics in Table S6).

Table S1. Numerical Values and Statistical Analysis of Data presented in Fig. 1 and S1

Table S2. Numerical Values and Statistical Analysis of Data presented in Fig. 2 and S2

Table S3. Numerical Values and Statistical Analysis of Data presented in Fig. 3 and S3

Table S4. Numerical Values and Statistical Analysis of Data presented in Fig. 4 and S4

Table S5. Numerical Values and Statistical Analysis of Data presented in Fig. 5 and S5

Table S6. Numerical Values and Statistical Analysis of Data presented in Fig. 6 and S6

Table S7. List of Reagents used in this Study




Figure S1






Figure S3




Figure S4




Figure S5




Figure S6

TABLE S1: Numerical values and statistical analysis of data presented in Fig. 1 and S1.

Figure	Statistical unit	Groups tested	Paired or unpaired	N	Unit	Mean	SEM
1c	Proportion of rat OTR positive astrocytes on 16 sections			1185	%	12,70	3,43587083
	Proportion of rat OTR positive neurons on 16 sections			1254	%	67,80	3,17608249
1g	onset time of responses	CeL astrocytes		21	s	42,500	15,853
	averages of offset time of responses	CeL astrocytes		21	s	435,762	67,643
S1a	Proportion of OTR positive			450	%	8,67	1,07

Figure	Statistical unit	Image	N	r_A^- [μ m]	R	c-score
S1b	Spatial distribution analysis of astrocytes within the CeL	Image 1	6	92 $\pm$ 22	0,75	1,16
		Image 2	8	116 $\pm$ 15	1,1	0,52
		Image 3	10	103 $\pm$ 9	1,03	0,49
		Image 4	12	100 $\pm$ 21	1,16	1,04
		Image 5	10	100 $\pm$ 23	1,05	0,33
		Image 6	12	104 $\pm$ 13	1,2	1,3
		Image 7	12	93 $\pm$ 13	1,07	0,47
		Image 8	12	69 $\pm$ 20	0,79	1,37
		Image 9	12	99 $\pm$ 26	0,99	0,05
		Image 10	13	94 $\pm$ 11	1,13	0,87
		Image 11	8	149 $\pm$ 43	1,4	2,18
		Image 12	9	145 $\pm$ 32	1,45	2,61

TABLE S2: Numerical values and statistical analysis of data presented in Fig. 2 and S2.

Figure	Statistical unit	Groups tested	Paired or unpaired	N	Unit	Mean	SEM	Test used	p-value
2a	proportion of responding astrocytes averaged per slices	TGOT	Unpaired	4	%	55,74	4,76	Independent Sample t-test	0,191
		TGOT+TTX		22		40,00	7,07		
	AUC ratio before/after treatment of responding astrocytes averaged per slices	TGOT	Unpaired	4	ratio	2,25	0,14	Independent Mann-Whitney U test	0,429
		TGOT+TTX		22		1,89	0,13		
	MAX value reached after treatment of responding astrocytes averaged per slices	TGOT	Unpaired	4	%	0,29	0,02	Independent Sample t-test	0,492
		TGOT+TTX		22		0,26	0,06		
	proportion of responding astrocytes averaged per slices	TGOT		3	%	40,00	10,00		
		TGOT+dOVT				2,78	2,78		
	AUC ratio before/after treatment of responding astrocytes averaged per slices	TGOT		3	ratio	1,25	0,24		
		TGOT+dOVT				0,88	0,01		
	MAX value reached after treatment of responding astrocytes averaged per slices	TGOT		3	%	0,25	0,09		
		TGOT+dOVT				0,29	0,17		
2b	proportion of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	%	55,74	4,76	Independent Mann-Whitney U test	0,892
		TGOT+TTX+PPADS		6		57,66	3,83		
	AUC ratio before/after treatment of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	ratio	2,25	0,14	Independent Sample t-test	0,636
		TGOT+TTX+PPADS		6		2,11	0,23		
	MAX value reached after treatment of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	%	0,29	0,02	Independent Mann-Whitney U test	0,566
		TGOT+TTX+PPADS		6		0,29	0,02		
	proportion of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	%	55,74	4,76	Independent Sample t-test	0,0001
		TGOT+TTX+CBX		8		16,52	5,78		
	AUC ratio before/after treatment of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	ratio	2,25	0,14	Independent Sample t-test	0,3541
		TGOT+TTX+CBX		5		2,17	0,51		
	MAX value reached after treatment of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	%	0,29	0,02	Independent Mann-Whitney U test	0,8793
		TGOT+TTX+CBX		5		0,30	0,04		
2c	Proportion of OTR positive astrocytes on 12 sections	OTR cKO + rAAV-GFAP-GFP	Unpaired	897	%	15,90	1,40	Independent Sample t-test	<0,0001
		OTR cKO + rAAV-GFAP-Cre-GFP	Unpaired	940	%	1,20	0,30	Independent Sample t-test	<0,0001
2d	proportion of responding astrocytes averaged per slices	TGOT in control mice	Unpaired	13	%	0,49	0,05	Independent Sample t-test	< 0,0001
		TGOT in OTR cKO + rAAV-GFAPp-Cre-GFP		10		0,09	0,02		
	AUC ratio before/after treatment of responding astrocytes averaged per slices	TGOT in control mice	Unpaired	13	ratio	1,24	0,18	Independent Mann-Whitney U test	0,1146
		TGOT in OTR cKO + rAAV-GFAPp-Cre-GFP		10		1,84	0,17		
	MAX value reached after treatment of responding astrocytes averaged per slices	TGOT in control mice	Unpaired	13	ratio	0,05	0,02	Independent Mann-Whitney U test	0,0766
		TGOT in OTR cKO + rAAV-GFAPp-Cre-GFP		10		0,11	0,05		
S2b	Cells capacitance	Astrocytes	Unpaired	82	pF	108,00	9,92	Independent Mann-Whitney U test	0,0002
		Neurons		20		47,43	5,72		
	Cells membrane resistance	Astrocytes	Unpaired	82	Mohm	22,25	2,39	Independent Mann-Whitney U test	<0.0001
		Neurons		20		210,80	43,22		
	Cells access resistance	Astrocytes	Unpaired	82	Mohm	10,17	0,79	Independent Mann-Whitney U test	0,4383
		Neurons		13		8,96	1,94		
	Cells resting potential	Astrocytes	Unpaired	20	mV	-85,32	1,13	Independent Mann-Whitney U test	<0.0001
		Neurons		12		-60,25	1,42		

bioRxiv preprint doi: https://doi.org/10.1101/2020.02.25.963884 ; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.									
S2d	proportion of responding astrocytes averaged per slices	TGOT+TTX+PPADS+Suramin+A438	Unpaired	22	%	55,74	4,76	Independent Mann-Whitney U test	0,066
				6		38,51	6,99		
S2e	rAAV-GFAPp-Cre-GFP efficiency on 12 sections	GluSyn + rAAV-GFAPp-Cre-GFP		1001	%	56,00	4,90		
	rAAV-GFAPp-Cre-GFP specificity on 12 sections	rAAV-GFAPp-Cre-GFP + GluSyn		977	%	96,20	2,10		
S2f	Proportion of OTR positive neurons on 12 sections	OTR cKO + rAAV-GFAP-GFP	Unpaired	688	%	89,10	4,80	Independent Sample t-test	0,7632
		OTR cKO + rAAV-GFAP-Cre-GFP		660		86,20	3,70		

TABLE S3: Numerical values and statistical analysis of data presented in Fig. 3 and S3.

Figure	Statistical unit	Groups tested	Paired or unpaired	N	Unit	Mean	SEM	Test used	p-value
3c	SICs frequencies across neurons recorded before and after treatment	Baseline	Paired	19	Hz	0,8457	0,2363	Wilcoxon signed rank test	0,0064
		20s λ 542nm light pulse				1,517	0,3781		
3d	APs frequencies across neurons recorded before and after treatment	Baseline	Paired	10	Hz	0,25	0,1256	Dunn's multiple comparisons	0,0003
		20s λ 542nm light pulse				0,745	0,3044		
		Wash				0,3	0,1287		
3e	IPSCs frequencies across neurons recorded before and after treatment	Baseline	Paired	9	Hz	1,955	0,358	Wilcoxon signed rank test	0,0038
		20s λ 542nm light pulse				3,368	0,635		
S3a	rAAV-GFAPp-C1V1-mCherry specificity on 9 sections	rAAV-GFAPp-C1V1-mCherry + ALDH1L1		323	%	98,452	0,802		
		rAAV-GFAPp-C1V1-mCherry + NeuN		318	%	0,000	0,000		
		rAAV-GFAPp-C1V1-mCherry efficiency on 9 sections		517	%	62,300	3,500		
S3c	APs frequencies across neurons recorded before and after treatment	Baseline+BAPTA	Paired	12	Hz	0,5292	0,1274	Dunn's multiple comparisons test	0,0395
		20s λ 542nm light pulse+BAPTA		12		0,6833	0,3054		
S3d	IPSCs frequencies across neurons recorded before and after treatment	Baseline+BAPTA	Paired	9	Hz	0,994	0,222	Holm-Sidak's multiple comparisons test	0,072
		20s λ 542nm light pulse+BAPTA		9		0,992	0,197		

TABLE S4: Numerical values and statistical analysis of data presented in Fig. 4 and S4.

Figure	Statistical unit	Groups tested	Paired or unpaired	N	Unit	Mean	SEM	Test used	p-value
4a1	SICs frequencies under TGOT across neurons recorded before and after treatment	Baseline	Paired	7	Hz	1,10	0,5088	Wilcoxon signed rank test	0,0156
		TGOT		7		2,50	0,6437		
		Baseline+Bapta	Paired	8	Hz	0,90	0,2478	Wilcoxon signed rank test	> 0,9999
		Bapta +TGOT		8		0,88	0,2698		
		TGOT	Unpaired	7	Hz	2,50	0,6437	Independent Mann-Whitney U test	0,0197
		Bapta +TGOT		8		0,88	0,2698		
4a2	APs frequencies under TGOT across neurons recorded before and after treatment	Baseline	Paired	9	Hz	0,43	0,1277	Wilcoxon signed rank test	0,0039
		TGOT		9		0,92	0,1732		
		Baseline+BAPTA	Paired	9	Hz	0,20	0,0898	Wilcoxon signed rank test	0,0938
		Bapta +TGOT		9		0,12	0,0595		
		TGOT	Unpaired	9	Hz	0,92	0,1732	Independent Mann-Whitney U test	0,0005
		Bapta +TGOT		9		0,12	0,0595		
4a3	IPSCs frequencies under TGOT across neurons recorded before and after treatment	TGOT	Unpaired	17	Hz	5,05	0,691	Independent Mann-Whitney U test	p<0,001
		Bapta +TGOT		17		1,31	0,351		
4b1	SICs frequencies under TGOT across neurons recorded before and after treatment	baseline in control mice	paired	8	Hz	1,10	0,3397	Wilcoxon signed rank test	0,0391
		TGOT in control mice		8		1,71	0,3669		
		Baseline in OTR cKO mice + rAAV-Cre-GFP	Paired	5	Hz	0,76	0,1939	Wilcoxon signed rank test	> 0,9999
		TGOT in OTR cKO mice + rAAV-Cre-GFP		5		0,75	0,1921		
		TGOT in control mice	Unpaired	8	Hz	1,71	0,3669	Independent Mann-Whitney U test	0,0862
		TGOT in OTR cKO mice + rAAV-Cre-GFP		5		0,75	0,1921		
4b2	APs frequencies under TGOT across neurons recorded before and after treatment	baseline in control mice	Paired	7	Hz	0,26	0,1071	Wilcoxon signed rank test	0,0156
		TGOT in control mice		7		0,82	0,1495		
		Baseline in OTR cKO mice + rAAV-Cre-GFP	Paired	11	Hz	0,35	0,0691	Wilcoxon signed rank test	0,8203
		TGOT in OTR cKO mice + rAAV-Cre-GFP		11		0,40	0,1263		
		TGOT in control mice	Unpaired	7	Hz	0,82	0,1495	Independent Mann-Whitney U test	0,032
		TGOT in OTR cKO mice + rAAV-Cre-GFP		11		0,40	0,1263		
4b3	IPSCs frequencies under TGOT across neurons recorded before and after treatment	Baseline in control mice	Paired	27	Hz	1,52	0,2621	Wilcoxon signed rank test	< 0,0001
		TGOT in control mice		27		2,80	0,3876		
		Baseline in OTR cKO mice + rAAV-Cre-GFP	Paired	16	Hz	1,72	0,3677	Wilcoxon signed rank test	0,9501
		TGOT in OTR cKO mice + rAAV-Cre-GFP		16		1,93	0,4365		
		TGOT in control mice	Unpaired	27	Hz	1,52	0,2621	Independent Mann-Whitney U test	0,0353
		TGOT in OTR cKO mice + rAAV-Cre-GFP		16		1,93	0,4365		
Figure	Statistical unit	Groups tested	Paired or unpaired	N	Unit	Mean	SEM	Test used	p-value
S3c	10 to 90% rise time of SICs across cells before and after treatment	Baseline	Paired	6	ms	31,68	7,158	Paired t-test	0,922
		TGOT		6		32,28	3,482		
	decay Tau of SICs across cells before and after treatment	Baseline	Paired	6	ms	113,78	25,468	Wilcoxon signed rank test	0,116
		TGOT		6		217,26	68,062		
	amplitude of SICs across cells before and after treatment	Baseline	Paired	6	pA	-27,79	7,134	Paired t-test	0,141
		TGOT		6		-17,22	1,304		

TABLE S5: Numerical values and statistical analysis of data presented in Fig. 5 and S5.

Figure	Statistical unit	Groups tested	Paired or unpaired	N	Unit	Mean	SEM	Test used	p-value
5c	SICs frequencies across CeL neuron before and after treatment	Baseline	Paired	7	n/min	1,100	0,509	Wilcoxon signed rank test	0,0156
		TGOT		7		2,500	0,644		
		Ifenprodil	Paired	10		0,425	0,084	Wilcoxon signed rank test	0,5703
		Ifenprodil + TGOT		10		0,367	0,136		
		Baseline	Unpaired	7		1,100	0,509	Independent Mann-Whitney U test	0,0409
		AP5		10		0,105	0,027		
5d	APs frequencies across CeL neuron before and after treatment	Baseline	Paired	9	Hz	0,433	0,128	Wilcoxon signed rank test	0,0039
		TGOT		9		0,917	0,173		
		Baseline AP5	Paired	7	Hz	0,464	0,108	Wilcoxon signed rank test	0,5313
		TGOT + AP5		7		0,407	0,150		
		TGOT	Unpaired	9	Hz	0,917	0,173	Mann Whitney test	0,0122
		AP5 + TGOT		7		0,407	0,150		
5e	IPSC frequencies across neurons recorded before and after	TGOT+DAAO	Paired	9	Hz	0,611	0,182	Wilcoxon signed rank test	0,0076
		TGOT+D-Serine				2,711	0,634		
Figure	Statistical unit	Groups tested	Paired or unpaired	N	Unit	Mean	SEM	Test used	p-value
S5a	proportion of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	%	55,739	4,764	Independent Sample t-test	0,037
		TGOT+TTX+AP5		4		82,292	10,259		
	AUC ratio before/after treatment of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	ratio	2,253	0,142	Independent Sample t-test	0,795
		TGOT+TTX+AP5		4		2,163	0,138		
	MAX value reached after treatment of responding astrocytes averaged per slices	TGOT+TTX	Unpaired	22	%	0,293	0,021	Independent Sample t-test	0,941
		TGOT+TTX+AP5		4		0,290	0,018		
S5b	IPSCs frequencies under TGOT across neurons recorded before and after treatment	TGOT1	Paired	7	Hz	8,900	1,500	Paired t-test	0,0529
		TGOT2				6,007	1,062		
	IPSC frequencies under TGOT across neurons recorded before and after treatment	TGOT		3	Hz	9,217	3,028		
		TGOT+dOVT				1,383	0,328		
S5c	IPSC frequencies under TGOT across neurons recorded before and after treatment	TGOT	Paired	7	Hz	12,371	2,558	Paired t-test	0,0308
		TGOT+AP5				6,121	1,018		
	IPSC frequencies under TGOT across neurons recorded before and after treatment	TGOT	Paired	12	Hz	11,300	1,336	Paired t-test	<0.001
		TGOT+DCKA				5,338	1,133		
S5d	IPSC frequencies under TGOT across neurons recorded before and after treatment	TGOT	Paired	8	Hz	7,316	1,811	Dunn's multiple comparisons	>0.05
		TGOT+DNQX				5,268	1,395		

TABLE S6: Numerical values and statistical analysis of data presented in Fig. 6 and S6.

Figure	Statistical unit	Groups tested	Time	Paw	Unit	N	Mean	SEM	Test used	p-value	
6a1	rat threshold for pain per group at different time points before and after drug(s) injection	SNI : Vehicle	CTRL	Left	g	12	79,194	1,649	Mixed-design ANOVA with Bonferroni adjustment for multiple comparisons	Time	<0,05
			0.3h			12	79,278	1,876		Time*Group	<0,05
			3.5h			12	79,417	2,315		Time*Paw	0,023
			24h			9	80,296	2,956		Time*Group*Paw	<0,05
		SNI : TGOT	CTRL			10	75,167	2,616			
			0.3h			10	122,633	4,530			
			3.5h			10	99,167	3,662			
			24h			9	76,963	2,443			
		Sham : Vehicle	CTRL			12	209,722	1,915			
			0.3h			12	205,556	1,614			
			3.5h			12	206,028	2,017			
			24h			10	206,233	3,004			
		Sham : TGOT	CTRL			11	208,467	2,189			
			0.3h			11	215,100	1,531			
			3.5h			11	211,000	1,705			
			24h			10	212,741	4,004			
		Sham : C1V1	CTRL			6	244,250	14,910	Mixed-design ANOVA with Bonferroni adjustment for multiple comparisons	Time	0,001
			0 min			6	234,333	17,736		Time*Group	0,007
			15 min			6	220,833	14,790		Time*Paw	0,054
			45 min			6	208,000	17,092		Time*Group*Paw	0,862
		SNI : C1V1	CTRL			10	79,233	6,104			
			0 min			10	82,267	3,183			
			15 min			10	79,733	2,708			
			45 min			10	80,000	2,774			
		SNI : Ctrl C1V1	CTRL			9	73,815	3,517			
			0 min			9	79,667	3,821			
			15 min			9	83,148	1,441			
			45 min			9	80,222	2,180			
S6a1	rat threshold for pain per group at different time points before and after drug(s) injection	SNI : Vehicle	CTRL	Right	g	12	216,139	1,774			
			0.3h			12	213,139	2,015			
			3.5h			12	212,361	2,283			

Figure	Statistical unit	Groups tested	Time	Paw	Unit	N	Mean	SEM	Test used	p-value			
S6a1	rat threshold for pain per group at different time points before and after drug(s) injection	SNI : TGOT	24h	Right	g	9	214,037	2,370	Mixed-design ANOVA with Bonferroni adjustment for multiple comparisons	Time	<0,05		
			CTRL			10	213,433	2,471		Time*Group	<0,05		
			0.3h			10	213,267	1,695		Time*Paw	0,023		
			3.5h			10	213,433	2,231		Time*Group*Paw	<0,05		
		Sham : Vehicle	24h			9	212,296	2,846	Mixed-design ANOVA with Bonferroni adjustment for multiple comparisons	Time			
			CTRL			12	207,222	1,543					
			0.3h			12	207,278	2,055					
			3.5h			12	207,417	1,970					
		Sham : TGOT	24h			10	211,033	1,975				Time*Group*Paw	
			CTRL			10	209,967	1,996					
			0.3h			10	212,033	1,572					
			3.5h			10	207,900	3,374					
		Sham : C1V1	24h			9	209,889	2,673					
			CTRL			6	247,167	13,531					
			0 min			6	254,278	10,786					
			15 min			6	232,667	10,491					
			45 min			6	222,278	4,576					
		SNI : C1V1	CTRL			10	182,767	10,286					
			0 min			10	216,200	11,015					
			15 min			10	186,400	11,411					
			45 min			10	185,700	11,335					
		SNI : Ctrl C1V1	CTRL			9	186,407	10,872					
			0 min			9	209,130	9,747					
			15 min			9	198,074	9,139					
			45 min			9	200,370	5,709					
6a2	Time spent in closed arm per rat	SNI : Vehicle + Ctrl C1V1			20	72,656	2,720	Mixed-design ANOVA with Bonferroni adjustment for multiple comparisons	Treatment	<0,0001			
		SNI : TGOT			9	59,635	2,181		Treatment * Surgery	0,0408			
		Sham : Vehicle + Ctrl C1V1		s	10	57,967	1,575						
		Sham : TGOT			8	56,711	2,458						
		Sham : C1V1			9	56,893	7,415						
		SNI : C1V1			7	51,067	6,594						

Figure	Statistical unit	Groups tested	Time	Paw	Unit	N	Mean	SEM	Test used	p-value	
S6a2	total distance per rat	SNI : Vehicle + Ctrl C1V1			m	20	956,437	297,666	Mixed-design ANOVA	Treatment	>0.05
		SNI : TGOT		9		1076,448	94,766	Treatment * Surgery		>0.05	
		Sham : Vehicle		10		1154,124	268,971				
		Sham : TGOT		8		1233,782	156,472				
		Sham : C1V1		9		1088,825	338,957				
		SNI : C1V1		7		1174,686	566,612				
6a3	Delta time spent in the paired chamber per rat	SNI : Vehicle + Ctrl C1V1			s	10	-95,47	56,206	Mixed-design ANOVA with Bonferroni adjustment for multiple comparisons	Treatment	<0.0001
		SNI : TGOT		8		267,438	74,858	Surgery		0,0316	
		Sham : Vehicle + Ctrl C1V1		13		-35,646	71,396	Treatment * Surgery		0,8856	
		Sham : TGOT		6		435,667	112,894				
		Sham : C1V1		5		476,7	69,796				
		SNI : C1V1		8		259,125	110,36				
S6a3	total distance per rat	SNI : Vehicle + Ctrl C1V1			m	10	15,16	1,591	Mixed-design ANOVA	Treatment	p=0.6272
		SNI : TGOT		8		27,67	11,08	Treatment * Surgery		p=0.5416	
		Sham : Vehicle		13		19,56	2,565				
		Sham : TGOT		6		15,37	3,165				
		Sham : C1V1		5		15,94	3,037				
		SNI : C1V1		8		13,84	2,052				

Figure	Statistical unit	Groups tested	Paired	N	Unit	Mean	SEM	Test used	p-value
S4a	IPSC frequencies under TGOT in sham and SNI animals	Sham TGOT	Unpaired	9	Hz	7,083	1,357	Independent Sample t-test	0,592
		SNI TGOT		9		6,639	2,183		
	basal IPSC frequencies in sham and SNI animals	Sham	Unpaired	16	Hz	4,322	1,461	Independent Sample t-test	0,484
		SNI		16		2,866	0,595		
	IPSC frequencies before and after TGOT in SNI animals	Baseline				2,167	0,677		0,0039
		TGOT	Paired	9	Hz	6,639	2,183	Paired t-test	
	IPSC frequencies before and after TGOT in sham animals	Baseline				3,339	0,694		0,0007
		TGOT	Paired	9	Hz	7,083	1,357	Paired t-test	

Figure	Statistical unit	Groups tested	Time	Paw	Unit	N	Mean	SEM	Test used	p-value	
6b1	mice threshold for pain per group at different time points before and after drug(s) injection	SNI OTR cKO mice + rAAV-Cre-GFP -> TGOT	CTRL	Left	g	13	1,923077	0,1915369	Mixed-design ANOVA with Bonferroni adjustment for multiple comparisons	Treatment	P < 0,0001
			0 min			13	2,138462	0,3024554	Treatment * Surgery	P < 0,0001	
			15 min			13	1,646154	0,09910845			
			45 min			13	2,646154	0,4852458			
			CTRL			5	1,08	0,08			
		SNI control mice -> TGOT	0 min	Left		5	1,32	0,08			
			15 min			5	1,08	0,08			
			45 min			5	1,32	0,08			
			Sham OTR cKO mice + rAAV-Cre-GFP -> TGOT			CTRL	8	4,5	0,3273268		
						0 min	Left		8	4,5	0,3273268
	15 min	8		3,8	0,646971						
	45 min	8		4,675	0,5842425						

Figure	Statistical unit	Groups tested	Time	Paw	Unit	N	Mean	SEM	Test used	p-value
6b2	Time spent in closed arm per mice		CTRL			6	5,333333	0,421637	Kruskal-Wallis test with Dunn's multiple comparisons	< 0,0001
		Sham control mice -> TGOT	0 min	Left	g	6	5,333333	0,421637		
			15 min			6	5	0,4472136		
			45 min			6	5	0,4472136		
		SNI OTR cKO mice + rAAV-Cre-GFP -> Vehicule				5	60,06	1,1		
		SNI OTR cKO mice + rAAV-Cre-GFP -> TGOT				7	59,51	0,5815		
		SNI control mice -> Vehicule				7	61,2	1,343		
		SNI control mice -> TGOT			s	8	47,58	1,173		
		Sham OTR cKO mice + rAAV-Cre-GFP -> Vehicule				5	60,56	1,078		
		Sham OTR cKO mice + rAAV-Cre-GFP -> TGOT				7	59,01	1,535		
6c2	Delta time spent in the paired chamber per mice	Sham control mice -> Vehicule				7	49,27	2,344	Kruskal-Wallis test with Dunn's multiple comparisons	0,0061
		Sham control mice -> TGOT				6	46,97	5,195		
		SNI OTR cKO mice + rAAV-Cre-GFP -> Vehicule				4	-108,3	126,3		
		SNI OTR cKO mice + rAAV-Cre-GFP -> TGOT				6	-31,75	25,34		
		SNI control mice -> Vehicule			s	5	-103,5	43,41		
		SNI control mice -> TGOT				5	282,8	95,21		
		Sham OTR cKO mice + rAAV-Cre-GFP -> Vehicule				5	-42,64	96,75		

Figure	Statistical unit	Groups tested	Time	Paw	Unit	N	Mean	SEM	Test used	p-value	
6c2	Delta time spent in the paired chamber per mice	Sham OTR cKO mice + rAAV-Cre-GFP -> TGOT				4	-153	178,1	Kruskal-Wallis test with Dunn's multiple comparisons	0,0063	
		Sham control mice -> Vehicule			s	5	-19,36	31,57			
		Sham control mice -> TGOT				8	338,1	95,74			
S6b1	mice threshold for pain per group at different time points before and after drug(s) injection	SNI OTR cKO mice + rAAV-Cre-GFP -> TGOT	CTRL	Right	g	13	4,307693	0,3820427	Mixed-design ANOVA with Bonferroni adjustment for multiple comparisons	Interaction	0,1894
			0 min			13	4,153846	0,1538462		Neuropathy	0,3355
			15 min			13	3,538461	0,2432521		Group	0,0246
			45 min			13	4,923077	0,2878198			
		SNI control mice -> TGOT	CTRL	5	4,4	0,4					
			0 min	5	4	0					
			15 min	5	3,6	0,4					
			45 min	5	4,4	0,4					
		Sham OTR cKO mice + rAAV-Cre-GFP -> TGOT	CTRL	8	4,5	0,3273268					
			0 min	8	4	0,3779645					
			15 min	8	4,5	0,5					
			45 min	8	4,25	0,4531635					
		Sham control mice -> TGOT	CTRL	6	5,333333	0,421637					
			0 min	6	5,333333	0,421637					
			15 min	6	5	0,4472136					
			45 min	6	4,666667	0,421637					

Figure	Statistical unit	Groups tested	Time	Paw	Unit	N	Mean	SEM	Test used	p-value
S6b2	total distance per mice	SNI OTR cKO mice + rAAV-Cre-GFP -> Vehicle			m	5	12,23	0,3877	Kruskal-Wallis test with Dunn's multiple comparisons	0,0378
		SNI OTR cKO mice + rAAV-Cre-GFP -> TGOT				7	12,68	0,8074		
		SNI control mice -> Vehicle				7	12,13	0,3323		
		SNI control mice -> TGOT				8	13,78	1,144		
		Sham OTR cKO mice + rAAV-Cre-GFP -> Vehicle				5	13,32	0,8245		
		Sham OTR cKO mice + rAAV-Cre-GFP -> TGOT				7	10,71	0,6737		
		Sham control mice -> Vehicle				7	11,57	0,2496		
		Sham control mice -> TGOT				6	12,34	1,525		
S6c2	total distance per mice	SNI OTR cKO mice + rAAV-Cre-GFP -> Vehicle			m	4	32,38	7,6	Kruskal-Wallis test with Dunn's multiple comparisons	0,3644
		SNI OTR cKO mice + rAAV-Cre-GFP -> TGOT				6	24,34	1,381		
		SNI control mice -> Vehicle				5	22,6	3,947		
		SNI control mice -> TGOT				5	30,68	3,288		
		Sham OTR cKO mice + rAAV-Cre-GFP -> Vehicle				5	27,61	2,189	Kruskal-Wallis test with Dunn's multiple comparisons	0,5496
		Sham OTR cKO mice + rAAV-Cre-GFP -> TGOT				4	31,13	5,921		
		Sham control mice -> Vehicle				5	34,82	5,108		
		Sham control mice -> TGOT				8	29,2	2,579		

TABLE S7: List of reagents used in this study

Experiments	Product	Full name	Company	Company reference	Concentration Stock	Concentration final	medium
Brain Slice preparation	Kynurenic acid	4-oxo-1H-quinoline-2-carboxylic acid.	Alomone labs	K-110	see materials and methods	see materials and methods	ACSF Bath medium
	Various salts and other products for ACSFs		Sigma-Aldrich	see company website	see materials and methods	see materials and methods	Bath medium
Calcium imaging on slices	Kolliphor® EL	Polyoxyl 35 hydrogenated castor oil	Sigma-Aldrich	C5135	see materials and methods	see materials and methods	ACSF Bath medium
	Oregon Green BAPTA 1		Thermo Fisher Scientific	O6807	see materials and methods	see materials and methods	ACSF Bath medium
	Rhodamine 2		Thermo Fisher Scientific	R1245MP	see materials and methods	see materials and methods	ACSF Bath medium
	Pluronic F127		Sigma-Aldrich	P2443	see materials and methods	see materials and methods	ACSF Bath medium
	Sulforhodamine 101		Sigma-Aldrich	S7635	1 mM in H2O	1 µM in ACSF	ACSF Bath medium
Patch-Clamp recordings	Various salts and other products for intracellular solution		Sigma-Aldrich	see company website	see materials and methods	see materials and methods	ACSF Bath medium
Brain slice experiments and in vivo intracerebral injection	A438079	3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methyl pyridine hydrochloride hydrate	Sigma-Aldrich	A9736	1 mM in H2O	1 µM in ACSF	ACSF Bath medium
	N-Ethylmaleimide		Sigma-Aldrich	E3876	100 mM in H2O	100 µM in ACSF	ACSF Bath medium
	1(S),9(R)-(-)-Bicuculline methiodide	(5S)-5-[(6R)-6,8-Dihydro-8-oxofuro[3,4-e]-1,3-benzodioxol-6-yl]-5,6,7,8-tetrahydro-6,6-dimethyl-1,3-dioxolo[4,5-g]isoquinolinium iodide	Sigma-Aldrich	14343	10 mM in H2O	10 µM in ACSF	ACSF Bath medium
	BAPTA	1,2-Bis(2-Aminophenoxy)ethane-N,N,N',N'-tetraacetic acid	Sigma-Aldrich	A4926	see materials and methods	see materials and methods	see materials and methods
	DAAO	D-amino acid oxidase	Sigma-Aldrich	A5222		0,15 U/ml, >1h30	ACSF Bath medium
	D-AP5	D-(-)-2-Amino-5-phosphonopentanoic acid	Abcam	ab120003	50 mM in H2O	50 µM in ACSF	ACSF Bath medium
	DCKA	5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid monohydrate	Sigma-Aldrich	D138	10 mM in DMSO	10 µM in ACSF	
	DNQX	6,7-Dinitroquinoxaline-2,3-dione	Abcam	ab120018	25 mM in DMSO	25 µM in ACSF	ACSF Bath medium
	dOVT	(d(CH ₂) ₅) ¹ ,Tyr(Me) ² ,Thr ⁴ ,Orn ⁸ ,des-Gly-NH ₂ ⁹)-Vasotocin trifluoroacetate salt	Bachem	H2908	1 mM in H2O	1 µM in ACSF	ACSF Bath medium / Intracerebral injection (0,5 µL)
	D-Serine		Sigma-Aldrich	S4250	100 mM in H2O	100 µM in ACSF	ACSF Bath medium

Experiments	Product	Full name	Company	Company reference	Concentration Stock	Concentration final	medium
Brain slice experiments and in vivo intracerebral injection	Ifenprodil	erythro-4-(2-(4-Benzylpiperidin-1-yl)-1-hydroxypropyl)phenol hemitartrate	Abcam	ab120111	3 mM in H2O	3 µM in ACSF	ACSF Bath medium
	PPADS	4-[[[4-Formyl-5-hydroxy-6-methyl-3-[(phosphonoxy)methyl]-2-pyridinyl]azo]-1,3-benzenedisulfonic acid tetrasodium salt	Sigma-Aldrich	P178	10 mM in H2O	50 µM in ACSF	ACSF Bath medium
	Suramin	Suramin sodium salt	Sigma-Aldrich	S2671	10mM in H2O	75µM	ACSF Bath medium
	TGOT	(Thr ⁴ ,Gly ⁷)-Oxytocin ; H-Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH ₂	Bachem	H-7710	0,4 mM in H2O	0,4 µM in ACSF	ACSF Bath medium / Intracerebral injection (0,5 µL)
	TTX citrate	Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-[1,3]dioxepino[6,5-d]pyrimidine	Abcam	ab120055	1 mM in H2O	1 µM in ACSF	ACSF Bath medium
Immunohistochemistry							
	Anti-GFAP antibody		Abcam	ab4674		1:500	PBS
	Anti-Glutamine Synthase		Merck Millipore	MAB302		1:500	PBS
	Anti Cav3.3 antibody		Alomone labs	ACC-009		1:200	PBS
	Alexa 555 Goat Anti-chicken		Abcam	ab150170		1:1000	PBS
	Alexa 488 Goat Anti-rabbit		Abcam	ab150077		1:1000	PBS
	Anti-ALDH1L1 antibody		Abcam	ab87117		1:500	PBS
	Alexa 680 Goat Anti-rabbit		Abcam	ab175773		1:1000	PBS
	Anti-NeuN antibody		Abcam	ab104225		1:1000	PBS
	Anti-Cre antibody	Gifted from Dr. Haikun Liu				1:1000	PBS
In situ hybridization	Denhardt's solution, lyophilised powder (50x)		Carl Roth	HP33.1	50x in H2O	5x	50% Formamide and 5x SSC
	Yeast tRNA		Invitrogen	15401011	10 mg/ml in H2O	0.25 mg/ml	50% Formamide and 5x SSC

Experiments	Product	Full name	Company	Company reference	Concentration Stock	Concentration final	medium
In situ hybridization	Glycine		Sigma-Aldrich	50046		7.5 mg/ml	PBS
	Proteinase K		PanReas AppliChem	A3830	10 mg/ml in PK buffer	0.5 µg/ml	PK buffer
	Triethanolamine		Carl Roth	6300		100 mM	H2O
	Acetic anhydride		Sigma-Aldrich	320102		0,25%	Acetylation buffer
	Ribonuclease A Solution		Sigma-Aldrich	R4642		20 µg/ml	RNase buffer
	2.5% Normal Goat Serum Blocking Solution		Vector Laboratories	S-1012		0.25%	Maleic acid buffer-Tween 20 (MABT)
	Blocking Reagent		Roche Diagnostics	11096176001	10% in MABT	1%	MABT
	Anti-Digoxigenin-POD		Roche Diagnostics	11207733910		1:200	0.25% NGS and 1% Blocking Reagent in MABT
	Imidazole		Merck Millipore	104716	10 mM in PBS	10 mM	PBS
	NHS-Rhodamine		Pierce Biotechnology, Thermo Fisher Scientific	46406	10 mg/ml in Dimethylformami de anhydrous	2 mg/ml	EtOH
	Tyramine hydrochloride		Sigma-Aldrich	T2879	10 mg/ml in Dimethylformami	0.6 mg/ml	EtOH